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Status epilepticus (SE), which is characterized by any prolonged and 
sustained seizure without recovery of consciousness, increases mortality risk 
during SE and in the 30-day period following seizure cessation.  Moreover, 
these seizures produce intense activation of the sympathetic nervous system 
(SymNS), diffuse myofilament damage, cardiac dysregulation, and autonomic 
nervous system (ANS) imbalance. It is proposed that these physiological 
effects of SE contribute to cardiac contractile dysfunctions, arrhythmias, and 
sudden death subsequent to seizure cessation.  Indeed, clinical reports have 
indicated an increased occurrence of ventricular arrhythmias at the time of 
death in SE patients, although the mechanism has not been elucidated. 
Potentially, a sympathetically mediated mechanism may result in a 
reversible cardiac dysfunction called cardiac stunning, which persists after a 
cardiac insult, leaving only subtle myofilament damage with normal blood 
flow.  Neurogenically mediated cardiac stunning results from prolonged 
sympathetic activation and hypersecretion of catecholamines, which over-
stimulate adrenoceptors on cardiac myocytes and induces tachycardic 
ischemia.  These changes cause diffuse myocyte damage, increased 
susceptibility to arrhythmias, and persistent risk of sudden cardiac death 
  
following the insult. We propose that a similar mechanism(s) may occur 
during SE, whereby prolonged seizure -induced sympathetic activation 
produces catecholamine mediated tachycardic ischemia, arrhythmias, 
myocardial stunning and ultimately an increased risk for mortality.  
Understanding how SE damages the heart and alters normal cardiac function 
may allow development of treatment paradigms and pharmacotherapeutic 
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Status Epilepticus and Mortality Risk Factors 
SE, which constitutes a medical emergency, is defined as any 
protracted or recurrent seizure lasting at least 30 min without recovery of 
consciousness (DeLorenzo, et al. 1996, Hauser 1990, Treiman, et al. 1998).  
The onset of clinical SE, however, can be evident within 5 min of persistent 
seizure activity (Sirven and Waterhouse 2003).  Several major causes of SE 
include acute systemic or neurological insults, metabolic disturbances, 
hyperthermia, hypoxia, stroke, head trauma, drug or alcohol toxicity, nerve 
gas exposure, and CNS infection (Lowenstein and Alldredge 1998).  
  This neurological emergency afflicts approximately 50 out of 100,000 
people annually (DeLorenzo, et al. 1996, Lowenstein and Alldredge 1998), 
with >13% experiencing a recurrent episode (Logroscino, et al. 2005, 
Lowenstein and Alldredge 1998),  40% developing epilepsy (Shorvon 1994), 
and 20% of patients dying (Towne, et al. 1994).  Further, a variety of life-
threatening physiological complications can arise during SE, such as 





Lothman 1995, Lothman 1990, Simon, et al. 1984), increased SymNS activity 
(Goodman, et al. 1999), and excessive catecholamine secretion (Shimizu, et al. 
2008, Simon, et al. 1984, Walton 1993). Despite these life-threatening 
conditions, SE-related mortality typically does not occur during or 
immediately following seizure cessation; on the contrary, over 90% of these 
deaths occur between 1 and 30 days after SE resolution (DeLorenzo, et al. 
1992, Fountain 2000, Logroscino, et al. 2005, Towne, et al. 1994).   
Unfortunately, the mechanisms that increase mortality risk following 
SE are unknown, though literature suggests that cardiac risk factors such as 
altered autonomic tone, myocardial stunning, and cardiac arrhythmias are 
important contributors (Aminoff and Simon 1980, Engrand and Crespel 2009, 
Kreisman, et al. 1993, Manno, et al. 2005, Metcalf, et al. 2009b, Painter, et al. 
1993, Walton, et al. 1995).  Understanding the relationship between various 
cardiac risks and complications associated with SE may allow development of 
therapies to prevent postseizure associated morbidity and mortality. 
 
 
Sympathetic Nervous System Mediated 
 Control of Cardiac Function 
Typically, SymNS mediated release of catecholamines will benefit the 
cardiovascular system and other tissues during strenuous activity by 
increasing circulation of oxygenated blood and nutrients. However, prolonged 





toxic, resulting in cardiac over-stimulation and damage (Rona 1985).  In 
sudden cardiac death, hyperactivation of the SymNS that induces cardiac 
damage has been proposed as a major mechanism underlying an increased 
susceptibility to arrhythmias and sudden death (Fountain 2000, Miakotnykh 
and Antiuf'ev 1991, Stollberger and Finsterer 2004b, Szucs, et al. 2006, 
Walton 1993).  Similarly, the intense and protracted activation of the SymNS 
observed during SE may produce a sudden and potentially prolonged 
hypersecretion of catecholamines (Anderson 2003, Dorian 2005, Goldberger 
1999, Goodman, et al. 1999, Manno, et al. 2005, Metcalf, et al. 2009b, Simon, 
et al. 1984, Xydas, et al. 2006) that over-stimulate β-1 adrenergic receptors 
and induce subtle myofilament damage.  However, the effects of protracted 
seizure activity on cardiac damage and contractile performance have not been 
systematically evaluated. 
 A thorough investigation of cardiac function is needed to formulate 
appropriate treatment paradigms during SE and post-SE. We propose that 
SE results in cardiac dysfunction through a neurogenic mechanism, whereby 
prolonged seizure activity induces SymNS-mediated tachycardia and 
presents as myocardial stunning.  Consequently, in the period following SE, 
patients who have developed myocardial stunning have an increased risk for 







Mechanisms of Neurogenically Mediated Cardiac Stunning 
Cardiac stunning (see Fig. 1.1) is a mechanical dysfunction that 
persists following a reperfusion injury, without irreversible cardiac damage, 
and despite return of normal cardiac perfusion  (Bolli and Marban 1999, 
Pomblum, et al. 2010).  Neurogenically mediated cardiac stunning produces 
alterations to both systolic and diastolic regional function (Bolli and Marban 
1999a, Przyklenk, et al. 1987).  Stunning is characterized by a reversible left 
ventricular dysfunction and increased plasma cardiac troponin I (cTnI) 
without gross cardiac damage (Bolli 1992, Bolli and Marban 1999, Gao, et al. 
1997).  Although the long-term prognosis for stunned myocardium is 
excellent, in the short-term cardiac dysfunction decreases output and alters 
electrophysiology.  These changes increase a patient’s risk for lethal 
arrhythmias and sudden cardiac death during this period (Jain, et al. 2004, 
Sato, et al. 1999).   
Neurogenically-mediated cardiac stunning may result from stress-
related activation of the SymNS and catecholamine secretions (Iga, et al. 
1995, Lee, et al. 2006).  For example,  neurally-mediated cardiac stunning 
has been reported following subarachnoid hemorrhage (Bulsara, et al. 2003, 
Donaldson and Pritz 2001, Lee, et al. 2006), cerebral infarctions (Wang, et al. 
1997), brain tumors (Chuang and Chao 2000), and Guillian-Barre syndrome 
(Bernstein, et al. 2000).  Although the mechanism is not fully understood, it 











Figure 1.1. The mechanism that produces neurogenically mediated 
cardiac stunning is caused by intense and prolonged activation of the SymNS.  
This results in protracted periods of catecholamine mediated tachycardic 
ischemia, hypertension, metabolic demand, and cardiac over-stimulation. 
Intense adrenergic stimulation causes cardiac injury by means of oxygen 
radical damage and activation of Ca2+ sensitive proteases (calpains), which 
damage contractile proteins (troponins) involved in excitation-contractile 
coupling. Damage or loss of functional troponins diminishes myofilament 
sensitivity to Ca2+, thereby, producing a reversible contractile dysfunction 
without gross cardiac damage. Recovery from stunning most likely requires 

































overdrive cause excessive stimulation of adrenergic receptors on myocytes.  
These effects produce prolonged positive inotropic  and chronotropic 
responses that induce tachycardic ischemia (Bolli 1990).  During prolonged 
periods of tachycardia, damaging levels of free radicals may accumulate near 
myofilaments and high levels of  intracellular Ca2+  may induce proteolysis of 
critical contractile proteins such as troponins, through activation of calpains 
(Bolli 1992, Bolli and Marban 1999, Kloner and Jennings 2001a, Kloner and 
Jennings 2001b, Kono, et al. 1994).  Damage or loss of functional troponins 
diminishes cardiac function, resulting in decreased myocyte sensitivity to 
Ca2+, altering both lusitropic and inotropic responses (Bolli 1990, Bolli 1992, 
Bolli and Marban 1999).  Recovery from myocardial stunning, therefore, may 
depend upon the synthesis of new troponins to restore normal myocardial 
contractions (Bolli 1992, Jain, et al. 2004).  It is proposed that during this 
recovery period patients have increased risk for sudden cardiac death due to 
altered cardiac function (Bolli 1992, Bolli and Marban 1999, Kloner, et al. 
2001, Pomblum, et al. 2010, Wittstein, et al. 2005). However, it is not clear if 
recovery of cardiac function results from cardiac remodeling. 
 The precise mechanism whereby SE produces cardiac stunning has 
not been fully elucidated.  Several studies have demonstrated that SE 
activates the SymNS, which increases catecholamine release in patients 
(Shimizu, et al. 2008) and in animals (Sakamoto, et al. 2008, Walton 1993). 





reported in patients following protracted seizures (Legriel, et al. 2008, 
Shimizu, et al. 2008), but has not been demonstrated in animals.  Moreover, 
these reports did not fully test for alterations in cardiac function, recovery, 
susceptibility to arrhythmias, or mortality risk.  Further, these reports did 
not investigate potential mechanisms of SE-induced cardiac stunning or 
pursue cardio-protective therapies.  
All of the aforementioned pathologies, including SE, have been 
proposed to produce stunning through a neurogenic mechanism in which 
sudden and prolonged activation of the SymNS and hypersecretion of 
catecholamines act to over-stimulate adrenergic receptors on cardiac muscle 
(Sakamoto, et al. 2008, Shimizu, et al. 2008, Simon 1985).   More Specifically, 
this dissertation addresses the proposal that SE-induced adrenoceptor 
overstimulation produces reversible cardiac dysfunction that can be 
characterized by subtle myocyte damage, cardiac conduction abnormalities, 
increased susceptibility to arrhythmias, and left ventricular dysfunction 
(Bolli and Marban 1999, Legriel, et al. 2008, Lemke, et al. 2008, Manno, et al. 
2005, Metcalf, et al. 2009a, Pomblum, et al. 2010, Walton, et al. 1995).   
 
 
SE-Induced Effects on Cardiac Regulation and Arrhythmias 
Accumulating evidence suggests a strong correlation between an 
increased occurrence of cardiac abnormities following SE and mortality 





hrs of SE termination over half of patients had specific electrocardiographic 
(ECG) changes including arrhythmias, conduction abnormalities, and 
ischemic patterns (Boggs, et al. 1993).  Boggs, et al. further identified two 
groups of SE patients who died of lethal arrhythmias following seizure 
cessation—those with preexisting coronary artery disease (CAD) and those 
without CAD (Boggs, et al. 1998).  These investigators concluded that in the 
days and weeks following SE, patients with no prior CAD had acute cardiac 
decompensation with only subtle myocardial damage (Boggs, et al. 1998), 
which can increase mortality risk. 
Additional clinical reports have observed a sudden and potentially 
prolonged activation of the SymNS during SE, which is pro-arrhythmic and 
produces hypersecretion of endogenous catecholamines (Anderson 2003, 
Dorian 2005, Goldberger 1999, Goodman, et al. 1999, Manno, et al. 2005, 
Simon, et al. 1984, Xydas, et al. 2006). This over-stimulates β-adrenergic 
receptors on cardiac muscle (Sakamoto, et al. 2008, Shimizu, et al. 2008, 
Simon 1985), elevating both HR and BP (Goodman, et al. 1990, Johnston, et 
al. 1997, Sakamoto, et al. 2008) for the duration of the seizure.  
Unfortunately, the mechanisms that produces subtle cardiac damage and 
increased susceptibility to ventricular arrhythmias following SE are not 
known. Ventricular arrhythmias are well established as a major cause of 
sudden cardiac death following neural activation and can result from 





function (Davis and Natelson 1993, Fredericks, et al. 2007, Hall 1983, 
Manno, et al. 2005).  As discussed above, one potential effect of SE-induced 
myofilament damage is cardiac stunning (Davis and Natelson 1993, Engrand 
and Crespel 2009, Goodman, et al. 1990, Lathers and Schraeder 1987, 
Manno, et al. 2005, Robakis and Hirsch 2006, Shimizu, et al. 2008, 
Stollberger and Finsterer 2004a, Walton 1993, Young, et al. 1985).   
Cardiac stunning is a contractile dysfunction that may result from 
decreased sensitivity to Ca2+ caused by myocyte damage (Gao, et al. 1995).  
This is because myocytes are entirely dependent on Ca2+ to regulate 
myofilament contraction and relaxation.   For cardiac myocytes to function 
normally, cytosolic Ca2+ concentrations need to be rigorously controlled (see 
Fig. 1.2).  During the myocyte action potential, extra cellular Ca2+ enters the 
myocyte through depolarization-activated (voltage-gated) ion channels 
producing inward Ca2+ currents.  These inward Ca2+ currents trigger 
ryanodine receptors to release Ca2+, which is bound to calsequestrin, from the 
sarcoplasmic reticulum (SR)—this is known as Ca2+ induced Ca2+ release. 
Increased cytosolic Ca2+  levels bind to troponin C in the sarcomere, causing a 
conformational change that moves tropomyosin out of the way so that the 
myosin cross bridges can attach to actin and produce muscle contraction—
this is known as excitation-contraction coupling.  Conversely, relaxation of 
the sarcomere is triggered by the removal of cytosolic Ca2+ (this is the period 













Figure 1.2. Ca2+ cycling in myocytes (see text for details). β-adrenergic 
receptor, βAR; muscarinic-2 receptor, M2; adenyl cyclase, AC; Na+/Ca2+ 
exchanger, NCX; sarcoplasmic reticulum, SR; ryanodine receptor, RyR; 











exchangers, and sequestration back into the SR via sarcoplasmic-
endoreticulum Ca2+ ATPase (SERCA).  Thus, the rate and concentration of 
Ca2+ that enters and exits the cytosol, which is primarily mediated by the SR, 
directly affects contraction and relaxation of myofilaments. Changes in Ca2+ 
movement, and thereby cardiac function, are regulated by phyosphorylation 
of various pumps, ions channels, and proteins on both the plasma membrane 
and the SR. One important regulatory mechanism is SymNS mediated β-
adrenergic stimulation by catecholamines, which is a stimulator G-protein 
coupled receptor that activates adenylate cyclase, producing cyclic AMP 
(cAMP) and activation of protein kinase A (PKA).  PKA phospharlytes the 
Na+/Ca2+ exchanger, L-type Ca2+ channels, phospholamban, and ryanodine 
receptors resulting in increased sensitivity to depolarization, faster efflux  of 
Ca2+ out of the cell, and faster influx of  Ca2+ into the SR.  This results in 
increase inotropy and chronotropy.  ParaSymNS mediated activation of 
Muscarinic receptors, which is an inhibitory G-protein coupled receptor that 
deactivates adenylate cylcase and opposes β-adrenergic stimulation, reduces 
cAMP  and PKA levels causing decreased inotropy and chronotorpy. Clearly, 
Ca2+ is an essential messenger that regulates cardiac electrical activity and is 
a direct activator of cardiac conduction, contraction and relaxation.  
Moreover, alterations in Ca2+ regulation can alter cardiac function and have 
been proposed as a major mechanism by which cardiac dysfunctions like 





Studies by Gao, et al. suggest that enhanced susceptibility to Ca2+ 
overload, which is an accumulation of intracellular Ca2+ that occurs during 
protracted tachycardia, supports the functional deterioration of myocardial 
stunning during intense inotropic stimulation (Gao, et al. 1995) and increases 
the arrhythmogenic activity of the heart by altering  cardiac electrical 
activity and function  (Anderson 2003, Bernstein, et al. 2000, Devinsky 2004, 
Freeman 2006, Gao, et al. 1995, Lathers and Schraeder 1987, Metcalf, et al. 
2009b, Nei, et al. 2000, Opherk, et al. 2002, Ryvlin, et al. 2006, Teplitz, et al. 
2005). However, there has not yet been any evaluation of diastolic Ca2+ 
regulation in myocytes during or after SE. By understanding the underling 
mechanism of SE-induced cardiac dysfunction, such as Ca2+ dysregulation 
and damaged excitation-coupling machinery, cardiac therapies and 
prognostic indicators could be identified that might lead to better prediction 
of who might be susceptible to seizure-related cardiac arrhythmias and 
mortality.  Moreover, the advent of a reliable biomarker would be a 
substantial advance in the prevention of death following SE. 
Another mechanism by which increased susceptibility to arrhythmias 
may occur following SE is altered ANS balance.  Sympathetic tone is the 
primary mechanism regulating left ventricular contraction (Fozzard 1986).  
Activation of the SymNS elevates endogenous levels of catecholamines, which 
act to increase blood pressure (BP), heart rate (HR), and myocardial 





seizures produce widespread and undifferentiated activation of the SymNS 
(Doba, et al. 1975, Goodman, et al. 1999).  The acute effects of 
hyperactivation of the SymNS result in catecholamine levels that are in the 
arrhythmogenic range and may contribute to sudden death (Simon, et al. 
1984).  Although the long-term post-SE effects on autonomic control and 
cardiac function are poorly understood, recent observations from our lab have 
demonstrated a shift toward sympathovagal tone resulting from paraSymNS 
withdrawal (Metcalf, et al. 2009b).  However, it is not clear if the increase in 
SymNS tone is a direct affect of damaged ANS brain centers, changes in 
afferent input, altered SymNS innervations of the heart, or unresponsive β-
adrenergic receptors.  
Importantly, an increase in SymNS tone combined with contractile 
dysfunction greatly increases the risk of lethal cardiac arrhythmias and 
sudden death (Lhatoo and Sander 2002, Stollberger and Finsterer 2004b, 
Szucs, et al. 2006, Thom, et al. 2003).  Thus, it is proposed that catecholamine 
overstimulation of cardiac receptors during SE and ANS imbalance post-SE 
may represent mechanisms that contribute to stunned myocardium and 
increased susceptibility to lethal ventricular arrhythmias in the period 












In the proposed mechanism of cardiac stunning, an increase in 
catecholamines, Ca2+ dysregulation, and generation of oxygen radicals in 
myocytes induce damage and proteolysis of troponins.  Damage or loss of 
functional troponins diminishes cardiac function by decreasing myofilament 
sensitivity to Ca2+ and muscle contractility.  The literature supports this 
cascade of events by demonstrating that therapy with a β-1 adrenergic 
receptor antagonist (Kyuma, et al. 2002, Vittone, et al. 2006, Yoshioka, et al. 
2008) may function to limit tachycardia caused by elevated adrenergic 
stimulation, thereby effectively decreasing SymNS tone on the heart 
(Adamson and Gilbert 2006, Dorian 2005).  We propose that cardioprotective 
therapy with an adrenergic blockade will provide protection from tachycardic 
ischemia and myofilament damage during SE, thereby preventing stunned 
myocardium, increased susceptibility to lethal ventricular arrhythmias, and 




SE is associated with significant mortality in the days and weeks 
following the acute event.  It has been proposed that SE-induced deaths 
result from subtle cardiac deficits and increased susceptibly to lethal 
arrhythmias; however, the mechanism(s) remains unknown.  One potential 





subsequent to an episode of SE is cardiac stunning.  Stunning results from 
altered ANS regulation of the heart, catecholamine-induced cardio-toxicity, 
over stimulation of myocytes, diastolic Ca2+ overload, and loss of functional 
troponins (Boggs, et al. 1998, Boggs, et al. 1993, Manno, et al. 2005, Walton 
1993).  Therefore, we propose that the hypersecretion of catecholamines 
during SE produces reversible decrements in cardiac function in the days and 
weeks following seizure cessation that is consistent with neurogenically-
mediated cardiac stunning, which can be prevented or attenuated with a β-1 
adrenergic antagonist.  Further, we hypothesize that myocyte damage caused 
by tachycardic ischemia during SE increases susceptibility to lethal 
arrhythmias through enhanced susceptibility to Ca2+   overload.  The 
following aims will be addressed in testing these hypotheses: 
1) determine if SE produces cardiac damage, increased 
susceptibility to arrhythmias, and diminishes cardiac 
hemodynamic and functional parameters that are 
consistent with neurogenically mediated cardiac 
stunning; 
2) determine if cardiac deficits and increased susceptibility 
to arrhythmias produced by SE are prevented by β-1 
adrenergic antagonist therapy;  
3) determine if SE results in intracellular myocyte Ca2+ 





The following Chapters of this dissertation provide the methods, 
results, and conclusions of studies that address these aims.  Chapter 2 
discusses the mechanism mediating detrimental cardiac effects of SE.  
Chapter 3 discusses the cardio-protective effects of β-1 adrenergic antagonist 
therapy during SE.  Chapter 4 addresses MRI scans of LV dysfunction 
following SE and recovery.  Chapter 5 discuss ex vivo measurements of Ca2+ 
transients following status epilepticus.  Chapter 6 provides the overall 
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MECHANISMS MEDIATING DETRIMENTAL CARDIAC  
 





Status epilepticus (SE) is a seizure or series of seizures that lasts 
longer than 30 min and frequently leads to sudden death in the period 
subsequent to seizure cessation. Even though the underlying mechanism is 
unknown, lethal cardiac arrhythmias have been implicated at the time of 
death. We propose as an overriding hypothesis that SE results in cardiac 
dysfunction through a neurogenically-mediated mechanism, wherein 
prolonged seizure activity leads to overstimulation of the heart. Such cardiac 
overstimulation induces a cardiomyopathy that increases the risk for lethal 
arrhythmias.  
Previous work in our lab has already demonstrated that SE results in 
cardiac damage via SymNS-mediated tachycardia within 90 min, and that SE 
increases susceptibility to lethal ventricular arrhythmias for at least 14 days 
following seizure cessation (Metcalf, et al. 2009). These experiments 





occurring during SE.  Further, these results suggest that seizure-induced 
cardiac injury is a mechanism for mortality during the period following SE.  
To characterize this potential mechanism, we monitored electrocardiogram 
(ECG) recordings for altered electrophysiology 10-14 days following SE 
cessation.  Additionally, we evaluated the protective effects of atenolol (AT) 
administration during SE on ECG alterations and on the susceptibility to 
lethal arrhythmias at 10-14 days following SE. Cardiac protection with 
atenolol demonstrated that the mechanism of SE-induced cardiac effects is 







Male Sprague-Dawley rats (225-250g) were obtained from a 
commercial supplier (Charles River, Wilmington, MA) and maintained at 
22oC on a 12hr:12hr, light:dark schedule. Animals were housed two to three 
per cage in Plexiglass cages before treatment and individually following SE. 
Animals were allowed ad libitum access to standard laboratory rat chow and 
water. The Institutional Animal Care and Use Committee at the University 







Induction of SE 
SE was induced by sequential administration with lithium and 
pilocarpine and has been thoroughly described elsewhere (Glien, et al. 2001, 
Kulkarni and George 1995).  Briefly, an injection of lithium (127 mg/kg ip; 
Sigma, St. Louis, MO) was given 18-24 hrs prior to pretreatment with 
methyl-scopolamine (2 mg/kg ip, Sigma) for 30 min, followed by 
administration of pilocarpine (30 mg/kg ip; Sigma) to induce SE.  Control 
(Cont) animals were administered 0.9% saline vehicle in place of pilocarpine.  
A modified Racine scale (Racine 1972) was used to evaluate seizure activity.  
Onset of SE was determined by the first grade III or greater seizure followed 
by more intense and persistent seizures. After 90 min of sustained SE, 
valproic acid (VPA 400 mg/kg ip; Sigma) was administered to terminate 
motor seizure activity. Cont animals received injections of VPA at similar 
time points. 
 Animal’s body weight, eating, and drinking were monitored throughout 
the experiments for up to 2 weeks.  Any hypodypsia and hypophasia were 
treated with administration of lactated ringer’s solution (3mL ip) and 













Twenty-four hours prior to induction of SE or Cont procedures, 
vascular catheterization was performed. Catheters were used to monitor 
blood pressure and heart rate during seizure activity; to administer atenolol 
(a β-1 adrenergic antagonist) or vehicle (saline); and to obtain blood samples 
for quantification of plasma cardiac troponin I (cTnI).  Catheters consisted of 
a 40-mm length of PE-10 cemented in PE-50 and filled with heparin/saline 
(50 U/mL).  To implant catheters, animals were anesthetized (Avertin, 300 
mg/kg; ip) and shaved on the inside of the right hind limb and the back of the 
neck.  Using blunt dissection, the femoral artery and femoral vein were 
exposed; next, catheters were inserted to approximately the level of the renal 
arteries and secured with surgical silk at the point of insertion. All catheters 
were led subcutaneously to exit between the scapulae.  Animals that 
underwent cardiac testing 10-14 days following SE were implanted with only 




Blood Pressure and Heart Rate 
Pulsatile BP was measured by a pressure transducer connected 
directly to the femoral artery catheter and was recorded by a Powerlab Data 





computer software (Lab Chart 7; ADInstruments) calculated mean HR and 




β1-adrenergic antagonist,  atenolol (1 mg/kg, iv), or vehicle (saline) was 
administered to SE or Cont animals immediately prior to the initiation of SE, 
then subsequently at 30-45 min intervals to maintain heart rate at 
preseizure levels.  Additional atenolol was administered if HR reached >10 
bpm from baseline. Once SE was terminated with VPA, no additional atenolol 
was administered.  
 
 
Measuring Cardiac Troponin I 
Cardiac damage was determined by measuring plasma concentrations 
of cardiac troponin I (cTnI), which is a well-established blood-borne indicator 
of cardiac myocyte damage (Antman 2002, O'Brien, et al. 2006, Sarko and 
Pollack 2002). Plasma samples (100 uL) were collected at 90 min following 
the initiation of seizure activity. Samples were stored at -80oC until they 
were used for assays. Plasma cTnI concentrations were measured using a 
commercially available ELISA kit manufactured for rats (Life Diagnostics, 









Evaluation of Cardiac Electrophysiology and Susceptibility to Arrhythmias 
Two weeks following SE, both Cont and SE animals were evaluated for 
changes in cardiac electrophysiology and susceptibility to experimentally 
induced ventricular arrhythmias by recording ECG activity at baseline and 
during an infusion of an arrhythmogenic agent. To prepare for cardiac 
testing, animals were anesthetized (α-chloralose; 40mg/kg, iv bolus; 
30mg/kg/hr maintenance iv) and implanted with femoral vein catheters. 
While animals were still under anesthesia, ECG electrodes were implanted 
by making two incisions ( 10 mm) in the skin of the upper right and lower 
left quadrants of the chest.  The exposed tips ( 5 mm) of two insulated silver 
wires were sewn with surgical silk thread into the thoracic muscles. The 
wires were placed subcutaneously around the body and externalized between 
the scapulae. The exposed ends of the wires were soldered to a connector.  
On the day following surgery, animals were anesthetized with 
Urethane (1.2 g/kg, ip). The ECG leads were connected to an amplifier and 
Powerlab 2/20 recording unit (ADInstruments, Colorado Springs, CO). After a 
60 min equilibration period, a 15 min baseline ECG recording was collected 
(see Fig. 2.1). From these recordings, QT and RR interval measurements 
were obtained.  The QT interval is the total time of ventricular depolarization 























 Figure 2.1.  Representative ECGs of ventricular arrhythmias induced 
by aconitine are shown, as follows: (Panel A) premature ventricular 
contractions (PVC; non-recurring QRS with no P wave); (Panel B) ventricular 
tachycardia (VT; a minimum sequence of P, QRS, PVC, PVC, PVC, PVC); and 









when the T-wave returns to the isoelectric value. The RR interval is the time 
between two successive heart beats. These variables were averaged across 10-
20 consecutive heart beats. Bazzett’s formula was used to correct the QT 
interval (QTc) for heart rate, QTc=QT/(RR)1/2.  QTc dispersion (Qtcd) was 
calculated by subtracting the minimum QTc from the maximum QTc for each 
animal. These measurements are well-documented indicators of increased 
risk for sudden cardiac death (Chugh, et al. 2009, Darbar, et al. 1996, de 
Bruyne, et al. 1998) and have established procedures for their evaluation in 
rodents (Chen, et al. 2009, da Silva Costa, et al. 2008, Volk, et al. 2001).   
Following baseline cardiac measurements, ECGs were continually 
recorded to evaluate susceptibility to experimentally-induced arrhythmias 
using the arrhythmogenic agent aconitine—an irreversible sodium channel 
agonist. Ventricular arrhythmias (see Fig. 2.1) were evoked by a 7 min 
infusion aconitine (5 μg/kg/min, iv) using a programmable syringe pump; this 
method has been shown to produce experimental ventricular arrhythmias in 
anesthetized rats (Grippo, et al. 2004, Shu, et al. 2004). Susceptibility to 
arrhythmias was determined by comparing the latency from the initiation of 
aconitine infusion to onset of: 1) premature ventricular contractions (PVC; 
non-recurring QRS with no P wave); 2) ventricular tachycardia (VT; a 
minimum sequence of P, QRS, PVC, PVC, PVC, PVC); and 3) ventricular 
fibrillation (VF; no discernable QRS complex).  These arrhythmias are 





Shu, et al. 2004, Takahara, et al. 1999). Once VF was reached, rats were 
immediately sacrificed with an high dose of Avertin (1000 mg/kg, iv). 
 
 
Evaluation of Cerebral Damage Induced by SE 
 Fluoro-Jade B immunohistochemistry was used to evaluated damage 
in the dentate gyrus of the hippocampus and used as an additional indicator 
of seizure intensity in SE animals treated with either atenolol or vehicle 
(saline). Twenty-four hours following SE termination, animals were 
anesthetized (Avertin, 300mg/kg; ip) and transcardially perfused with 300 
mL of 0.1M neutral phosphate buffered 10% formalin.  After this, the brains 
were rapidly excised and post-fixed overnight in 10% formalin + 20% sucrose. 
Using a cryostat, 6-8  coronal tissue sections (40 um) were collected from the 
rostral, mid, and caudal regions of the hippocampus, mounted to charged 
slides, and allowed to air dry for 30 min. These sections were stained with 
Fluoro-Jade B following the manufacturer’s directions (Chemicon 
International, Billerica, MA).  A confocal microscope equipped with a 
fluorescein isothiocyanate (FITC) filter (510-560nm band pass) was used to 
visualize the treated section.  Neurodegeneration was quantified in each 













HR and BP 
 The maximum mean BP and maximum HR during 90 min of seizure 
activity in SE and Cont animals can be seen in Fig. 2.2.  SE animals treated 
with vehicle (saline) demonstrated a significant increase in both HR and BP 
in response to prolonged seizure activity.  Atenolol administration during SE 
prevented any increase in HR when compared to Cont, Cont + AT, and SE + 
AT treated animals, but it did not lower the BP response. No observable 
difference in seizure intensity observed by atenolol therapy during SE and 
seizure termination with VPA was similar among all groups.  
 
 
SE-Induced Cardiac Damage 
Fig. 2.3 demonstrates an increase in plasma cTnI within 60 min of SE 
initiation and indicates cardiac myocyte damage. In contrast, atenolol 
administration during SE eliminated seizure-related increases in plasma 
cTnI, which were comparable to Cont, and Cont+AT treated animals.  These 
data demonstrate that SE induces cardiac damage during seizure activity, 













 Figure 2.2.  Maximum mean arterial blood pressure (Panel A; MABP) 
and heart rate (Panel B; BPM) during vehicle-treated status epilepticus (SE; 
n=10) in rats, and at similar time points in Cont (n=7), and in atenolol 
treated Cont (Cont+AT; n=4) and atenolol treated SE (SE+AT; n=5) animals. 




















 Figure 2.3. Cardiac troponin I  (cTnI) plasma concentrations obtained 
60 min following the onset of seizure activity in vehicle-treated status 
epilepticus (SE; n=6) and at similar time points in vehicle-treated control 
(Cont; n=4) rats, and in atenolol treated Cont (Cont+AT; n=4) and atenolol 






Cardiac Electrophysiology—QTc Duration and QTc Dispersion 
  QT interval prolongation and dispersion are clinically accepted as 
prognostic indicators of increased risk of arrhythmogenic electrical activity 
and sudden death. QT interval has been corrected for HR using Bazett’s 
formula. Fig. 2.4 graphically represents the measurements of QTc duration 
and QTc dispersion, recorded 12-14 days following SE or at equivalent time 
points in Cont (n=7), Cont+AT (n=7), SE (n=8), and SE+AT (n=7) animals. SE 
animals demonstrated a significant QTc prolongation and increased QTc 
dispersion for up to 12-14 days when compared to Cont, Cont + AT, and SE + 
AT groups. Atenolol administration during SE, however, prevented QTc 
prolongation and increased QTc dispersion following seizure cessation when 
compared to vehicle-treated SE animals. These data demonstrate that 
atenolol is cardioprotective against SE -induced cardiac effects produced 
through a β-1 receptor mediated mechanism. 
 
 
Susceptibility to Arrhythmias 
 Fig. 2.5 illustrates the mean latencies to aconitine induced ventricular 
arrhythmias 12-14 days following SE cessation. We previously demonstrated 
that aconitine infusion in Cont and SE rats resulted in a decreased latency to 
the 1st PVC , VT and VF, which indicates an increased susceptibility to lethal 
ventricular arrhythmias (Metcalf, et al. 2009). Atenolol administration 









 Figure 2.4. Corrected QT interval (Panel A; QTc) and QTc dispersion 
(Panel B; QTcd) measured 12-14 days following vehicle-treated control (Cont; 
n=7), atenolol treated Cont (Cont+AT; n=7), vehicle-treated SE (n=8) and 
















 Figure 2.5. Latency from the initiation of aconitine administration to 
the 1st premature ventricular contraction (1st PVC), ventricular tachycardia 
(VT), and ventricular fibrillation (VF) measured 12-14 following vehicle-
treated control (Cont; n=4), atenolol treated Cont (Cont+AT; n=4), vehicle-
treated SE (n=6) and atenolol treated SE (SE+AT; n=5) rats. **p<0.01 
















arrhythmias observed in SE animals 12-14 days later. These data 
demonstrate that β-1 receptor blockade, which inhibits SymNS effects on the 




 Representative confocal photomicrographs of Fluoro-Jade B-stained 
hippocampal sections of Cont and SE animals treated with atenolol or vehicle 
are shown if Fig. 2.6 (Panel A).   The mean number of Fluoro-Jade B  positive 
neurons/section are summarized in Fig. 2.6 (Panel B).  Results demonstrated 
a significant and similar increase in damaged neurons in both SE and SE + 
AT treated animals when compared to Cont and Cont + AT treated rats, 
which has no positive stained neurons.  These data indicate that atenolol 




These data demonstrate that cardiac therapy during prolonged seizure 
activity with a β-1 adrenergic antagonist limited sympathetically mediated 
tachycardia, SE-induced cardiac damage, and arrhythmogenic cardiac 
disturbances, and normalized susceptibility to experimentally induced 
ventricular arrhythmias for up to 10-12 days following seizure cessation.  











 Figure 2.6.  Representative confocal photomicrographs (Panel A) of 
positive Fluoro-Jade B stained neurons in the dentate gyrus of the 
hippocampus in control (Cont) and rats undergoing status epilepticus (SE) 
treated with either vehicle (Veh) or atenolol (AT).  Mean number of positive 
Fluoro Jade B stained neurons per hippocampal section in vehicle-treated 
control (Cont; n=4), atenolol treated Cont (Cont+AT; n=4), vehicle-treated SE 








and not by reduced seizure intensity, as brain damage and motor seizure 
activity was equivalent in all SE animals. However, this needs to be further 
supported by video or EEG recordings to quantitated seizure severity and 
duration. These results support the proposal that intense activation of the 
SymNS during SE causes overstimulation of β-1 adrenoceptors on the heart 
and induces acute cardiac damage, altered cardiac electrophysiology, and 
increased susceptibility to ventricular arrhythmias.  
 Prolonged elevation of HR and BP demonstrates activation of the 
SymNS in these experiments during 90 min of continuous seizure activity.  
These findings are well supported by both clinical and animal research 
(Goodman, et al. 1990, Johnston, et al. 1997, Sakamoto, et al. 2008, Shimizu, 
et al. 2008).  In clinical reports, SE induces reversible cardiac damage 
(Aminoff and Simon 1980, Earnest, et al. 1992, Legriel, et al. 2008, Manno, et 
al. 2005) and increases risk of lethal arrhythmias in the weeks following 
seizure cessation (Earnest, et al. 1992, Fountain 2000, Hall 1983, Kumar, et 
al. 2005, Lathers and Schraeder 2002, Scorza, et al. 2008).  Although 
detrimental cardiac effects were similar to those already observed in patients 
and animals, these experiments also demonstrate that cardioprotective 
therapy with a β-1 receptor blockade prevents SE-induced cardiac deficits. 
Moreover, these results support the proposal that the mechanism of SE-
induced adverse cardiac effects is sympathetically mediated, and suggest a 





The QT interval represents the total time for ventricular 
depolarization and repolarization to occur and is an index of action potential 
duration (APD). Prolonged QTc and increased QTcd are both indicators of 
increased arrhythmogenic cardiac electrical activity and thereby are 
prognostic predictors of increased risk of ventricular arrhythmias that cause 
sudden death. The present experiments demonstrate that SE produced both 
prolonged QTc and increased QTcd in rat hearts for at least 12 days following 
seizure cessation. Moreover, evidence of SymNS mediated alterations to APD 
during SE, is demonstrate by treatment during seizure with atenolol to 
prevent β-1 receptor induced tachycardia, which completely ablated APD 
prolongation and normalized QTc and QTcd to Cont values. One mechanism 
that alters QT interval and increases susceptibility to sudden cardiac death is 
myocardial ion channel remodeling. Cardiac myocyte ion channel remodeling, 
due to SymNS activation, mimics cardiac ion channelopathies that result 
from primary genetic mutation or acquired inactivation to ion subunits and 
interacting proteins—for example, loss of function in potassium channels in 
long QT syndrome (Schimpf, et al. 2009, Ueda, et al. 2008, Vatta, et al. 2006, 
Wu, et al. 2008). Indeed, evidence of diminished Kv4.2 potassium channel 
expression has been demonstrated in rat myocytes at 1 and 2 weeks following 
SE (Bealer, et al. 2010). Taken together, these results suggest a candidate 
mechanism by which protracted seizures increase risk of sudden cardiac 





facilitator, via β-adrenergic stimulation by catecholamines, and an acquired 
electrical substrate, via myocyte ion channel remodeling.  
The mechanism by which SymNS hyperactivation produces 
arrhythmogenic myocardial damage, remodeling and altered cardiac function 
is not understood.  In SE, prolonged seizures induce positive inotropic and 
chronotropic responses on myocardial function, as indicated by increased HR 
and dP/dt (Goodman, et al. 1990, Johnston, et al. 1997, Sakamoto, et al. 
2008).  In addition, seizure activity increases BP, and thereby afterload, 
which can further stress the heart (Kloner, et al. 2001, Kloner and Jennings 
2001a, Kloner and Jennings 2001b).  In these experiments, cardiac therapy 
with a β-1 receptor antagonist, which limits seizure-induced tachycardia but 
not afterload, provided protection from neurogenically mediated cardiac 
damage, alteration in electrophysiology, and normalized susceptibility to 
arrhythmias.  These results suggest that increased afterload alone is not 
contributing to cardiac stunning; however, the effects of a catecholamine-
induced chronotoropic response without the altered pressor response are 
unknown. 
Brain damage has been previously reported in lithium pilocarpine 
induced SE (Druga, et al. 2010, Nairismagi, et al. 2006, Poirier, et al. 2000). 
There are likely several mechanisms mediating CNS damage during seizure 
activity including acute metabolic disturbances, hyperthermia, hypoxia, 





(Lowenstein and Alldredge 1998).  Consequently, it was unknown if 
preventing SE-related tachycardia during motor seizure activity would 
exacerbate CNS damage by altering the pressor response and limiting 
cerebral perfusion. However, these data demonstrated that when HR was 
maintained at preseizure levels, the pressor response was not significantly 
altered and BP remained elevated in all SE animals. Moreover, evaluation of 
CNS damage with Fluoro-Jade B demonstrated that atenolol administration 
during SE did not significantly alter hippocampal damage compared to 
vehicle-treated SE animals. These data demonstrate that cardiac protective 
therapy with atenolol, which blocks sympathetically mediated tachycardia, 
does not increase risk nor provide protection from CNS neuronal death or 
damage as a result of altered or diminished perfusion pressure. 
Cardiac protection observed in these studies is attributed to peripheral 
antagonistic effects of atenolol and not alteration in seizure activity. Even 
though β-adrenergic receptor antagonists (Nakamura, et al. 2008, Raju, et al. 
1998) that cross the blood brain barrier alter seizure threshold (De Sarro, et 
al. 2002, Luchowska, et al. 2002, Luchowska, et al. 2001),  atenolol was 
selected since it does not readily penetrate the blood brain barrier and 
thereby does not alter seizure threshold or seizure frequency (De Sarro, et al. 
2002, Luchowska, et al. 2002).  These data indicate that atenolol treatment 
during SE did not alter seizure-related cerebral damage or SE intensity. 





in MAP, which suggest that SymNS activity was maintained during seizure 
activity and that the mechanisms of cardiac protection is primarily due to β-1 
blockade on cardiac myocytes and not a reduced central effect.  However, 
from a clinical treatment paradigm administration of a β-adrenergic 
antagonist, which does cross the blood brain barrier, may potentially provide 
both cardiac and cerebral protection during seizure activity.   
These data are consistent with the proposal that SE causes a stress 
cardiomyopathy that is characterized by increases in plasma cTnI, altered 
cardiac electrical activity, and a reduction in cardiac function—all of which 
increase susceptibility to ventricular arrhythmias and sudden death. 
However, to determine if SE produces neurogenically mediated cardiac 
stunning, cardiac hemodynamic needed to be evaluated (see Chapter 3). 
Moreover, these data suggest a prolonged period of cardiac dysfunction 
following SE in rats, which is consistent with clinical reports that lethal 
arrhythmias contribute to mortality within 30 days of the episode. Further, 
these experiments suggest that cardiac therapy during seizure activity may 
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β-1 BLOCKER THERAPY INHIBITS STATUS EPILEPTICUS 
 





The precise mechanisms producing myocardial stunning following SE 
have not been determined in humans. SE has been proposed to produce 
stunning through a neurogenic mechanism in which a sudden and prolonged 
activation of the SymNS and hypersecretion of catecholamines act to over-
stimulate β-adrenergic receptors on cardiac muscle (Sakamoto, et al. 2008, 
Shimizu, et al. 2008, Simon 1985).  Adrenoceptor overstimulation can 
produce cardiac dysfunction characterized by subtle myocyte damage, cardiac 
conduction abnormalities, increased susceptibility to arrhythmias, and left 
ventricular (LV) dysfunction (Bolli and Marban 1999, Legriel, et al. 2008b, 
Lemke, et al. 2008, Manno, et al. 2005, Metcalf, et al. 2009a, Pomblum, et al. 
2010, Walton, et al. 1995). While the first of those three characteristics has 
been reported to occur as a result of SE in rats (Bealer, et al. 2010b, Metcalf, 





antagonist therapy on cardiac function have not been previously 
demonstrated in animal models of SE.  
Therefore, the present experiments were designed to determine if LV 
dysfunction, which mimics myocardial stunning in humans, occurs in a rat 
model of self-sustaining limbic status epilepticus (SSLSE) in rats. Further, 
these studies were designed to demonstrate that administration of a β-1 
receptor antagonist prevents cardiac dysfunction caused by SE-induced 
sympathetic activation. Twenty-four hours following SE, cardiac function in 
rats was determined by measuring cardiac output (CO) and recording LV 
pulse pressure (LVP), mean arterial pulse pressure (MAP), and ECG activity. 
These recordings were further evaluated for HR, QTc, the first derivative of 
the maximum rate of LV pressure development over time (LVP dP/dt max), 
which is a measure of LV contractility, and the first derivative of the 
minimum rate of LV pressure development over time (LVP dP/dt min), which 







 Male Sprague-Dawley rats (175-225 g) were purchased from a 
commercial supplier (Charles River, Wilmington, MA). These rats had ad 





in animal quarters maintained at 23oC and a 12hrs:12hrs, light:dark cycle. 
All experimental procedures were approved by the Institutional Animal Care 
and Use Committee at the University of Utah. 
 
 
 SSLSE Protocol 
 Rats were implanted with an electrode in the left amygdala, which 
served as both a means of electrical stimulation to induce SSLSE and 
recording electroencephalographs (EEG).  To implant electrodes, rats were 
anesthetized (Avertin, 300mg/kg, ip) and their heads shaved. They were then 
placed into a stereotaxic frame. A 2-3 cm midline incision was made to expose 
the skull.  A small burr hole was made in the skull directly above the 
amygdala. Adjacent to the hole, three small plastic anchor screws were 
inserted into the skull. A bipolar stimulating electrode (9mm length, with 1 
mm gap; Plastics1 Inc.) was stereotaxically implanted in the lateral nucleus 
of the left amygdala (anterior-posterior -3.6, medial-later 5.0, dorsal-ventral -
6.5, from bregma and the dura) through the hole and fixed into place with 
dental acrylic. Once the dental acrylic had hardened the skin was closed with 
wound clips and an antibiotic ointment was applied.  Finally, a cap (Plastics 
1 Inc.) was placed on the electrode to keep it clean.  After all surgeries, 
animals were administered Baytril (antibiotic) and Rimadyl (NSAID) and 
returned to their home cages.  Rats were allowed to recover for a minimum of 





SSLSE Induction Protocol 
 After recovery from electrode implantation, rats were connected to 
stimulating (IsoMax-100 Biphasic Stimulus Isolator) and EEG recording 
equipment (Powerlab 2-20; ADInstruments). In animals undergoing SSLSE, 
an electronic switch (Grass Instruments) was used to alternate between 
stimulation and EEG recording modes. Stimulations consisted of 40 min of a 
100 msec train of 1 msec biphasic square wave pulses at 600 µA, delivered at 
60 Hz every 0.5 sec. Electrographic seizures were evaluated from the EEG. 
Motor seizure activity was visually monitored during the stimulation period 
and quantified using the Racine scale (Racine 1972). Motor seizures typically 
began intermittently within the first few minutes of stimulation, and 
progressed in severity and duration until the seizures became persistent and 
self-sustaining. After 40 min the stimulation was stopped and EEGs were 
collected. Successful SSLSE induction was ascertained by monitoring 
spontaneous motor seizure behavior and recurrent, spontaneous spike wave 
activity in EEGs (Nissinen, et al. 2000). Following 90 min of continuous 
SSLSE, animals were administered valproic acid (VPA; 400 mg/kg ip; Sigma, 
St. Louis, MO) to terminate seizure activity.  All animals were then returned 
to their home cages, where food and water ingestion were monitored.  All 
animals were supplemented with an injection of 3 mL lactated Ringer’s 
solution (ip) and offered water-softened palatable breakfast cereal (Froot 





identical treatment at concurrent time points, but did not receive electrical 
stimulation of the amygdala. 
 
 
Evaluation of Seizure Severity by EEG Activity 
  EEG activity was evaluated by counting the number of spontaneous 
spike wave occurrences over a 3 min period during SSLSE at 5, 30, 60, and 90 
min after the amygdala stimulation was discontinued. 
 
 
β-1 Adrenergic Blockade with Atenolol 
 SSLSE animals were administered atenolol (1 mg/kg; SSLSE+AT) or 
vehicle (SSLSE+VEH) via tail vein injection immediately prior to the 
initiation of seizure activity. Additional atenolol was given at 30-35 min 
intervals to maintain baseline HR during seizures. HR was monitored from 
ECG recordings. Cont rats received saline injections at similar intervals.  
 
 
ECG Recording Protocol  
 ECG electrodes were implanted 24 hrs after SSLSE and at an 
equivalent time point in Cont rats. Leads were constructed from two 
insulated silver wires with one end of both wires soldered to a connector. To 
implant these leads, rats were anesthetized with urethane (1.2 g/kg, ip), and 
incisions ( 10 mm), were made in shaved areas on the upper and lower 





through the incisions and sutured into the thoracic muscles. The other ends 
(connector end) of the wires were attached to a Powerlab 2-20 chart recording 
unit (ADInstruments).  The ECG signals were amplified (50x), filtered (1-




CO  Determination 
Immediately after ECG leads were implanted and while the animals 
were still under anesthesia, CO was measured by thermodilution using a CO 
module obtained from ADInstruments. Briefly, the neck was shaved, and an 
incision ( 2-3 cm) was made on the right side of the neck. The right jugular 
vein and right carotid artery were dissected out, occluded with surgical silk, 
and the vessels opened. Next, the jugular vein was cannulated with 
polyethylene tubing (PE-50; filled with heparin, 50 U/ml), which was 
advanced to just below the right atrium. Next, a thermistor probe was 
inserted through the carotid artery to the aortic arch. The other end of the 
probe was connected to the CO module and a Powerlab 2-20 chart recorder 
(ADInstruments).  Following a 5 min calibration period, the temperature 
indicated by the thermistor probe was recorded continuously. In each animal, 
several thermodilution curves were generated, by sequential injections of 150 
uL room temperature saline into a jugular vein catheter. CO was calculated 





LV and Aortic Pulse Pressure Recordings 
After CO measures were collected, aortic and LV pulse pressure 
parameters were recorded using an arterial catheter and pressure 
transducer. The previously exposed carotid artery was cannulated with 
polyethylene tubing (PE-50; filled with heparin, 50 U/ml) and cannula 
inserted to the level of the aortic arch or into LV.  The other end of the 
catheter was directly connected to a pressure transducer attached to a 
Powerlab Data Acquisition System (ADInstruments) and Windows computer.  
Arterial and LV pulse pressures were recorded for 3-5 min at each location. 
From these recordings, MAP, LVP dP/dt max, LVP dP/dt min were calculated 
using Chart software (ADInstruments).  
 
 
Evaluation of QT Intervals 
From ECG recordings, QT, QRS and RR interval measurements were 
obtained.  The QT interval is the total time of ventricular depolarization and 
repolarization, starting at the beginning of the Q wave and terminating when 
the T-wave returns to the isoelectric value. QRS corresponds to conduction 
time of the LV. The RR interval is the time between two successive heart 
beats and was used to determine HR. These measurements were averaged 
across 10-20 consecutive heart beats. Bazzett’s formula was used to correct 
the QT interval (QTc) for heart rate, QTc=QT/(RR)1/2.  QTc dispersion (Qtcd) 





each animal. These measurements are well-documented indicators of 
increased risk for sudden cardiac death (Chugh, et al. 2009, Darbar, et al. 
1996, de Bruyne, et al. 1998) and have established procedures for their 





All data are presented as means ±SEM.  Differences between two 
means were evaluated with the Student t-test, and differences among 
multiple means determined following one-way or multiple-factor analysis of 
variance for repeated measures. A Newman-Keuls a posteriori test was used 
to determine differences between individual means following ANOVA. A 






Seizure Activity  
 Motor seizure activity during SSLSE was characterized by persistent 
stage 3-4 Racine scale seizures with randomly occurring stage 5 seizures 
throughout the 90 min period. Spike wave activity was self-sustained and 
persisted for 90 min in all SSLSE+VEH and SSLSE+AT animals. There were 





occurrences between the SSLSE+VEH and SSLSE+AT group (see Fig. 3.1). 




Cardiac Electrical Activity  
 Twenty-four hours after SSLSE termination, prolonged QTc and QTcd 
were measured from ECG recordings and summarized in Fig. 3.2.  No 
significant difference was found in the QRS interval 24 hrs following seizure 
cessation. Representative data is demonstrated in Fig. 3.3.  These data 
indicated significant prolongation in cardiac action potential duration in all 
animals that underwent SSLSE and saline injections (SSLSE+VEH; n=6) 
when compared to control animals (Cont, n=6).  Conversely, administration of 
atenolol to animals during SSLSE (SSLSE+AT, n=6) significantly decreased 
the QTc interval and QTcd prolongation at 24 hrs when compared to 
SSLSE+VEH treated animals. However, conduction was still significantly 
prolonged in SSLSE+AT animals compared to Cont rats. These data are 
















 Figure 3.1. These data show the total number of spike wave/min at 5, 
60, and 90 min during self-sustained seizure activity in SSLSE and atenolol 
treated (SSLSE+AT) animals.  These data demonstrate that atenolol did not 




















 Figure 3.2. QT interval corrected for heart rate (panel a; QTc) and QTc 
dispersion (panel b; QTcd) in control rats (Cont; n=6) and 24 hrs after rats 
underwent SSLSE pus saline injections (SSLSE+VEH; n=6) or treatment 
with atenolol (SSLSE+AT; n=6. *=p<0,05 for SSLSE vs. Cont and SSLSE vs. 















 Figure 3.3. Representative ECGs showing QRS and QT invervals 24 
hrs following seizure cessation in SSLSE, SSLSE+AT treated and Cont rats.    
QT prolongation indicates increase in action potential duration (see Fig. 3.2) 
and QRS prlongation indicates conduction slowing.  Although there was a 
tendancy for QRS prolongation in the SSLSE rats, it was not significant 




































































































































































Cardiac Hemodynamic and LV Functional Parameters 
 Twenty-four hours after SSLSE termination, hemodynamic and 
functional parameters were determined from carotid artery and LV 
recordings and are summarized in Fig. 3.4. These data indicate that all 
animals that underwent SSLSE and saline injections (SSLSE+VEH, n=6) 
had significant cardiovascular dysfunction including increased MAP, 
decrease CO, and decreased LVP dP/dt max, when compared to Cont (n=5) 
animals. Further, treatment of the animals with atenolol during SSLSE 
(SSLSE+AT, n=5) significantly prevented all of these cardiac alterations 
when compared to SSLSE+VEH. These data are consistent with the 
hypothesis that catecholaminergic blockade, with atenolol, inhibits SE-
related tachycardia and protects the heart from SE-induced contractile 





 These studies are the first to demonstrate diminished cardiac 
ventricular function in a rat model of SE that is consistent with SE in 
humans.  Further, these studies show that administration of the β-1 receptor 
antagonist atenolol during SSLSE prevents development of cardiac 
contractile dysfunctions, which occur within 24 hrs after SE. Together these 












 Figure 3.4. Cardiac output (a; CO), first derivative of the maximum LV 
pressure over time (b; LVP dp/dt max) and first derivative of the minimum 
LV pressure over time (b; LVP dp/dt min), mean arterial pressure (c; MAP), 
and heart rate (d; HR) were measured in control rats (Cont; n=5) and 24 hrs  
after rats underwent SSLSE plus saline injections (SSLSE+VEH; n=6) or 
treatment with atenolol (SSLSE+AT; n=5). *= p<0.05 for SSLSE vs. Cont and 































prevention of adverse cardiac effects caused by SE, which may reduce 
mortality risk in patients who experience SE.  
These observations further support the proposal that SE results in 
diminished cardiac function through a neurogenic mechanism in which 
increased sympathetic tone and high levels of plasma catecholamines induce 
over-stimulation of the β-adrenergic receptor on the heart.  Thus, without β-
receptor antagonist therapy during SSLSE, prolonged cardiac over-
stimulation can produce detrimental cardiac stunning in humans (Bolli 1990, 
Bolli 1992, Ishiguro and Morgan 2001, Kloner, et al. 2001, Legriel, et al. 
2008b, Schulz and Heusch 1995, Shimizu, et al. 2008, Vittone, et al. 2006, 
Wittstein, et al. 2005). Previous reports have demonstrated that in patients 
and animals, SE is associated with subtle myofilament damage (Bealer, et al. 
2010b), conduction abnormalities (Boggs, et al. 1993), and susceptibility to 
lethal arrhythmias (Gao, et al. 1995, Legriel, et al. 2008a); however, this is 
the first report of the effect of SE on diminished LV hemodynamic 
parameters and changes in cardiac electrophysiology in a non-
chemoconvulsive animal model of SE.  This suggests that the cardiac damage 
produced during the Li-pilocarpine model of SE results from seizure activity 
and not the muscarinic effects of pilocarpine. 
Alterations in LV cardiac function were determined by measuring 
dP/dt during diastole and systole (Borges, et al. 2006, Dowell, et al. 1975), 





that SSLSE significantly reduced cardiac contraction, prolonged action 
potential duration, and produced a deficit in LV cardiac pumping efficiency 
indicative of cardiac stunning within 24 hrs—this was demonstrated by 
diminished CO, prolonged QTc, and decreased LVP dP/dt max and min, 
respectively. Further, all of these adverse cardiac effects —except for LVP 
dP/dt min—were prevented by atenolol administration during SSLSE, which 
limits catecholamine mediated effects on myocytes. The observed alteration 
in LV impaired relaxation is a novel finding among diseases contributing to 
LV dysfunction and correlates well with the observed prolongation in action 
potential duration. However, the mechanism by which SSLSE induces 
diminished LVP dP/dt min in both the SSLSE and SSLSE+AT treated 
animals is not clear, especially given that animals received cardioprotective 
therapy.  Lathers et al. have reported cardiac autonomic nerve centers do not 
always respond in a predicable manner in animal models of seizures (Lathers 
and Schraeder 1982, Lathers and Schraeder 1987). It is likely that both blood 
pressure and cardiac control centers, which are not protected with a selective 
β-1 antagonist therapy, are damaged during SSLSE and contribute to altered 
cardiac function independent of cardiac damage.  Further investigation of SE 
induced alteration during seizure activity on vascular smooth muscle, pressor 
responses,  and sympathoexcitatory brain sites is needed to understand their 
respective contribution to altered cardiac function and increased mortality.  





with mortality (Manno, et al. 2005, Metcalf, et al. 2009a, Metcalf, et al. 
2009b). Atenolol therapy may thereby reduce mortality risk through cardiac 
protection from β-receptor over-stimulation, however additional studies are 
needed to understand the effects of  SE on vascular damage or alterations to 
cardiac autonomic control centers.  Collectively, the current observations 
combined with previous reports (Bealer, et al. 2010a, Metcalf, et al. 2009a, 
Metcalf, et al. 2009b) demonstrate that SSLSE produces all of the 
aforementioned characteristics of neurogenically mediated cardiac stunning 
within 24 hrs of seizure cessation. 
In the SSLSE+AT group, significant changes in QTc and QTcd, which 
were less than the SSLSE group but more than Cont, were observed. The 
mechanism that increases QTc and QTcd in SSLSE + AT rats is not clear. It 
is possible that a residual increase in SymNS drive may persist following 
concurrent cessation of SSLSE and termination of atenolol administration, 
which alters cardiac electrophysiology. Alternatively, a catecholamine 
independent mechanism may alter QTc and QTcd.  Regardless of the 
mechanism, we have previously reported that rats receiving atenolol 
administration during 90 min of SE did not exhibit any changes in QTc or 
QTcd at 10 days following seizure cessation (Bealer, et al. 2010b). Therefore, 
the alterations in QTc and QTcd observed in the atenolol treated animals in 





Cardiac protection observed in these studies is attributed to peripheral 
antagonistic effects of atenolol and not alteration in seizure activity. Even 
though β-adrenergic receptor antagonists (Nakamura, et al. 2008, Raju, et al. 
1998) that cross the blood brain barrier alter seizure threshold (De Sarro, et 
al. 2002, Luchowska, et al. 2002, Luchowska, et al. 2001), atenolol was 
selected since it does not readily penetrate the blood brain barrier and does 
not alter seizure threshold or seizure frequency (De Sarro, et al. 2002, 
Luchowska, et al. 2002). These experiments demonstrate that the 
administration of atenolol did not alter spike wave frequency, initiation or 
progression for 90 min of SSLSE. Moreover, progressive administration of 
atenolol did not significantly alter or attenuate either spike wave activity 
frequency or observed motor seizure behavior during the seizures.    
Results of cardiac electrophysiology and hemodynamic data presented 
in this Chapter are consistent with cardiac alterations found in Chapter 2, 
which demonstrated  cardiac damage during SE, chronic alterations in 
cardiac action potential duration, and increased susceptibility to arrhythmias 
10-14 days following SE.  Results presented in Chapter 3 extend these 
findings and demonstrate that cardiac effects occur acutely. This supports the 
proposal that SE increases the susceptibility to mortality in the period 
following seizure cessation (Chin, et al. 2004).  Together data from Chapters 
2 and 3 demonstrate a contractile dysfunction characterized by 





diminished CO;  however to determine if SE results in cardiac stunning, 
which is defined as reversible contractile dysfunction without gross damage, 
cardiac recovery needed to be evaluated (see Chapter 4). Further, these data 
demonstrate pathological substrates that increase susceptibility to 
arrhythmias, however the mechanism remains unknown (see Chapter 5).   
In summary, during SE, there is a sudden and prolonged increase in 
SymNS activity, which can result in overstimulation of β-adrenergic receptors 
on the heart causing subtle myofilament damage (Metcalf, et al. 2009a), 
arrhythmogenic electrical activity, and cardiac contractile dysfunction—all of 
which are characteristics of cardiac stunning. Although the exact mechanism 
is not yet clear, it is proposed that the positive chronotropic and inotropic 
effects of prolonged exposure to high levels of catecholamines result in 
tachycardic ischemia. Additionally, catecholamine-induced cardiac 
dysfunction is indicative of neurogenically mediated cardiac stunning 
(Ishiguro and Morgan 2001, Wittstein, et al. 2005). Further, our results 
suggest that during SSLSE, antagonism of β-1 adrenoceptors can prevent 
cardiac dysfunctions and thereby may reduce stunned myocardium and 
decrease mortality-associated risk factors. Finally, these results provide a 
rationale for cardiac monitoring during and following SE and indicate a 
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MRI IMAGING OF LEFT VENTRICULAR DYSFUNCTION 
 





 Prolonged seizure activity is associated with intense activation of the 
SymNS that produces cardiac damage, tachycardia, hypertrophy, altered 
cardiac electrical activity, and increased susceptibility to arrhythmias. These 
cardiomyopathies are indicative of neurogenically mediated cardiac stunning, 
which is a reversible contractile dysfunction that persists after reperfusion of 
a short and severe ischemic insult to the heart in which no gross damage has 
occurred (Bolli and Marban 1999, Pomblum, et al. 2010).  In the short term, 
cardiac stunning produces a contractile dysfunction that increases mortality 
risk; conversely, the long-term prognosis for stunned myocardium is complete 
recovery of cardiac function (Jain, et al. 2004).  Results in Chapter 3 
demonstrate decreased LV function 24 hrs post-SE in animals that is 
indicative of stunning; however, due to the invasive nature of cardiac 
catheterization and the use of urethane (from which animals are not allowed 





recovery were not feasible. Thus, to further characterize cardiac deficits and 
to investigate cardiac recovery following SE we used a noninvasive technique, 
magnetic resonance imaging (MRI).  This noninvasive technique allowed 
repeated cardiac measurements following SE and during recovery.  Further, 
this technique allowed cardiac myocardium to be viewed for gross cardiac 
damage acutely and remodeling following 45 days of recovery. We 
hypothesized that 90 min of SE would produce cardiac effects similar to 
stunning within 24 hrs, from which rats recover over several weeks. Although 
the acute cardiac effects have been previously described following SE 
(discussed in Chapter 3), cardiac recovery following SE termination has not 
been thoroughly investigated in rats.  Cardiac function was measured using 
functional MRI imaging of the short axis of the left ventricle (LV) at 24 hrs, 
10 and 45 days following SE. These images were evaluated for chamber 
volume, LV ejection fraction, LV stroke volume, myocardial edema, and gross 
remodeling.  Additionally, T2 weighted MRI scans of the brain were collected 
and evaluated for brain damage and edema over the same period. Together, 
these results demonstrate recovery of cardiac dysfunction and progress of 

















Male Sprague-Dawley rats (225-250 g) were obtained from a 
commercial supplier (Charles River, Wilmington, MA) and maintained at 
22oC on a 12 hr:12 hr, light:dark schedule. Animals were housed two to three 
per cage in Plexiglas cages before treatment and individually following SE. 
Animals were allowed ad libitum access to standard laboratory rat chow and 
water. The Institutional Animal Care and Use Committee at the University 
of Utah approved all experimental procedures. 
 
 
Induction of SE 
SE was induced by sequential administration with lithium and 
pilocarpine, and has been thoroughly described elsewhere (Glien, et al. 2001, 
Kulkarni and George 1995). Briefly, an injection of lithium (127 mM/kg ip; 
Sigma, St. Louis, MO) was given 18-24 hrs prior to pretreatment with 
methyl-scopolamine (2 mg/kg ip, Sigma) for 30 min, followed by 
administration of pilocarpine (30 mg/kg ip, Sigma) to induce SE.  Control 
(Cont) animals were administered 0.9% saline vehicle in place of pilocarpine.  
A modified Racine scale (Racine 1972) was used to evaluate seizure activity.  
Onset of SE was determined by the first grade III or greater seizure followed 





valproic acid (VPA; 400 mg/kg ip, Sigma) was administered to terminate 
motor seizure activity. Cont animals received injections of VPA at similar 
time points. 
Each animal’s body weight, eating, and drinking were monitored 
throughout experiments for up to 45 days.  Any hypodypsia and hypophasia 
were treated with administration of lactated Ringer’s solution (3 mL ip) and 




MRI procedures were performed with the assistance of the Small 
Animal Imaging Facility at the University of Utah.  MRI scans were 
performed to determine changes in indices of heart function in all animals at 
24 hrs, 10 and 45 days following SE cessation. To perform MRI protocols, 
each animal was exposed to 4% isoflurane until an appropriate plane of 
anesthesia was induced and was maintained with 2-3% isoflurane. Each rat 
was placed prone in the MRI equipment on a pressure sensor to measure 
respiration, and a pulse oximeter was attached to the rat’s foot to monitor HR 
and oxygen saturation.  
The heart was imaged using a Bruker Biospec 7T/30 cm system 
operated with Bruker AVANCE II electronics (Bruker BioSpin MRI GmbH, 
Ettlingen, Germany).  A Bruker birdcage quadrature resonator (72 mm inner 





MRI GmbH, Ettlingen, Germany).  CINE scans of the heart were acquired 
using black blood FLASH scan with retrospective gating. The instrument 
settings were as follows: repetition time (TR) = 31 ms, echo time (TE) = 2.8 
ms, number of averages (NEX) = 4, field of view (FOV) = 8 cm x 8 cm, in-
plane resolution = 408 x 312 microns, slice thickness = 1.5 mm, number of 
movie frames = 15. Prospective gating was achieved using SAII monitoring 
and gating systems (SA Instruments, Stony Brook, NY, USA). 
Resultant CINE MRI sequences were used to calculate left ventricular 
volume throughout the cardiac cycle using freely available software, Segment 
v1.8 (Segment; http://segment.heiberg.se). The left ventricle was analyzed in 
a semi-automated manner by an investigator blinded to the treatment 
groups.  Wall thickness was measured at the mid-ventricular level in a short-
axis view; papillary muscles were excluded from these measures.  Stroke 
volume was calculated by subtracting the LV end-diastolic volume from LV  
end-systolic volume. Ejection fraction was calculated by dividing stroke 
volume by end-diastolic volume. 
MRI scans of the brain were also performed to evaluate damage in all 
animals at 24 hrs, 10 and 45 days following SE cessation. Cerebral spinal 
fluid and edema appear brighter than white and gray matter in T2-weighted 
images. Twelve coronal T2-weighted images of the brain were obtained using 





field of view 2.5 x 2.5 cm) with in-plane resolution of 156 x 200 microns, and 




All data are presented as means±SEM.  Comparison between baseline 
control measurements and subsequent values were analyzed with a two-way 
analysis of variance for repeated measures. A Bonferonni posteriori test was 
used to determine differences in replicate means following ANOVA.  A p<0.05 






LV Chamber Volume  
Fig. 4.1A-C summarizes LV chamber volumes measured from MRI 
scans at 15 time points throughout diastole and systole at baseline and at 24 
hrs, 10 and 45 days following 90 min of SE.  Within 24 hrs, animals that had 
undergone SE (24 hrs, n=5) had a significant decrease in LV chamber volume 
throughout diastole and systole compared to Cont animals (24 hrs, n=5). 
However, by days 10 and 45 all animals that had undergone SE (10 days, 
n=3; 45 days, n=3) exhibited a similar chamber volume compared to Cont (10 
days, n=3; 45 days, n=3). A plot of LV chamber volume vs. one complete heart 





animals that underwent SE when compared to Cont animals (see Fig. 4.1A), 
which recovers within 10 days. These results are consistent with the 
hypothesis that SE induces a reversible contractile dysfunction characterized 
by diminished LV stroke work that is indicative of cardiac stunning within 24 
hrs in rats. Additionally, these cardiac deficits recover within 10 days and did 
not produce any apparent chronic alteration in LV function.  
 
 
LV Wall Thickness 
LV wall thickness was measured from MRI scans at 15 time points 
throughout systole and diastole at baseline and at 24 hrs, 10 and 45 days 
following 90 min of SE in rats and is summarized in Fig. 4.1D-F. SE produced 
a significant increase in LV wall thickness within 24 hrs, in all SE animals 
(24 hrs, n=5; 10 days, n=3; 45 days n=3) throughout diastole and systole 
when compared to Cont animals (24 hrs, n=5).  However, at 10 and 45 days 
animals that had undergone SE (10 days, n=3; 45 days n=3) exhibited a 
similar LV wall thickness when compared to Cont (10 days, n=3; 45 days 
n=3). A plot of LV wall thickness vs. time demonstrates LV hypertrophy 
within 24 hrs, which recovers in 10 days, in animals that underwent SE 
when compared to Cont animals (see Fig. 4.1D).  These results are consistent 
with the proposal that SE induces a reversible LV diastolic dysfunction in 
rats similar to cardiac stunning in humans within 24 hrs following SE 













Figure 4.1. These graphs show the LV chamber volume (Panels A, B, and C) 
and the average wall thickness (Panels D, E, and F) measured from MRI 
images through diastole and systole starting at end-systole in SE animals (A, 
n=5; B, n=3; C, n=3) and Cont (A, n=5; B, n=3; C, n=3) at 24 hrs, 10 and 45 




































dysfunction and hypertrophy is significantly recovered within 10 days and 
does not produce any apparent chronic alteration in wall thickness.  
 
 
Stroke Volume and Ejection Fraction 
 Fig. 4.2 summarizes LV ejection fractions and stroke volumes using LV 
chamber volumes measured from MRI scans at 15 time points throughout 
systole and diastole at 24 hrs, 10 and 45 days following 90 min of SE in Cont 
(24 hrs, n=5; 10 days, n=3; 45 days, n=3) and SE rats (24 hrs, n=5; 10 days, 
n=3; 45 days, n=3).  SE produced a significant increase in LV ejection fraction 
and a decrease in stroke volume, characterized by a decrease in both end-
diastolic volume and stroke volume, in SE animals at 24 and 10 days 
following seizure cessation. No significant difference between SE and Cont 
rats was observed by 45 days. These results are consistent with the 
hypothesis that SE induces both a reversible diastolic dysfunction similar to 
cardiac stunning in humans following SE cessation. Further, these data 
demonstrate that SE-induced cardiac dysfunction is significantly recovers 
and does not produce any apparent chronic cardiac dysfunction. 
 
 
T2 Weighted Brain Images 
 Fig. 4.3 shows representative images of T2 weighted coronal images 












 Figure 4.2. Ejection Fraction (Panel A) and LV Stroke Volume (D) 
measured from MRI images in SE animals (24 hrs, n=5; 10 days, n=3; 45 
days, n=3) and Cont (24 hrs, n=5; 10 days, n=3; 45 days, n=3) following 90 
min of SE.  *= p<0.05 for SE 24 hrs vs. Cont  24 hrs.  ‡= p<0.05 for SE 10 











 Figure 4.3. Representative brain MRI images taken using T2 weighted 
brain scans of four different rats at baseline and at 24 hrs, 10 and 45 days 
following 90 min of SE. Bright white areas indicate edema, particularly in the 










baseline (n=5)  and at 24 hrs (n=5), 10 (n=3) and 45 (n=3) days following 90 
min of  SE.  These are the same animals that underwent MRI analysis of the 
heart in Fig. 4.1.  These images show considerable edema in the hippocampus 
and cortex in all animals that underwent SE procedures within 24 hrs, which 
persists through 10 days and becomes notably worse by 45 days. Additionally, 
these images also show an enlargement of the ventricles by day 45 following 
SE.  Although cardiac function appears to recover within 10 days following 




Fig. 4.4 shows a representative image of a short axis view of the LV 
mid-cavity scans taken from both Cont and SE animals.  All MRI scans taken 
from Cont (n=11) and SE (n=11) animals were visually evaluated for gross 
anatomical changes. No visible gross cardiac damage or infarctions were 
noted in any MRI image in any animal.  These data support the proposal that 
SE produces only subtle and reversible cardiac damage that induces short-
term contractile dysfunction—such as stunning and impaired lusitropy.  
 
 
HR During MRI Scans 
The average HR in Cont (24 hrs, n=5; 10 days, n=3; 45 days n=3) and 
SE (24 hrs, n=5; 10 days, n=3; 45 days n=3) animals was determined over 10-











 Figure 4.4. Representative images of cardiac mid-ventricular short axis 
slices during diastole at 24 hrs, 10 and 45 days following 90 min of SE.  These 
images show increased wall thickness of the LV at 24hrs, but not at 10 or 45 
days following SE.  Further, no gross anatomical damage or remodeling of the 
LV was observed by 45 days. LV wall measurements were taken from 



































 Figure 4.5. Average HR determined during MRI scans in Cont (24 hrs, 
n=5; 10 Days, n=3; 45 Days, n=3) and SE (24 hrs, n=5; 10 Days, n=3; 45 Days, 
n=3) animals while under isoflurane anesthetic (Cont, 1.5-2.0%; SE 2.5-3.0%). 









animals demonstrated a significant increase in HR independent of 
respiration rate (maintained at 40-46 breaths/min ) or oxygen saturation 
(maintained at >97%)  while under anesthesia, and needed more isoflurane 





Results from these experiments demonstrate that within 24 hrs 
following seizure termination, SE induces reversible LV contractile 
dysfunctions that are similar to cardiac stunning in humans.  SE produces 
both systolic and diastolic dysfunctions characterized by decreased LV stroke 
work, altered inotropy, impaired lusitropy, and increased LV wall thickness 
without irreversible gross cardiac damage.  These data further demonstrate 
that these cardiac deficits recover within 1-10 days following SE cessation, as 
there were no apparent indications of altered contractility or gross 
remodeling of the LV beyond 10 days.  Although cardiac recovery was 
demonstrated, cerebral edema in the hippocampus, cortex and ventricles 
persisted for more than 45 days, which suggests that CNS damage may alter 
the ANS and affect cardiac response.  Together, these data support the 
proposal that SE induces a recoverable contractile dysfunction similar to 
Together, these data support the hypothesis that SE induces a recoverable 
contractile dysfunction similar to cardiac stunning in humans, which 





reduce mortality risk factors, SE may produce more chronic alterations to 
autonomic balance, due to persistent CNS damage, which may prolong 
cardiac risk factors associated with sudden cardiac death. 
Several studies in both humans and animals have demonstrated that 
SE produces intense activation of the sympathetic nervous system (Benowitz, 
et al. 1986), increased plasma catecholamine levels (Shimizu, et al. 2008, 
Walton 1993), tachycardia, and hypertension (Metcalf, et al. 2009a, 
Sakamoto, et al. 2008).  In more recent studies, neurogenically mediated 
cardiac stunning has been reported in patients following an episode of SE 
(Legriel, et al. 2008, Shimizu, et al. 2008).  These data support the proposal 
that an increased chronotropic and inotropic effect during SE produces 
tachycardiac ischemia and cardiac injury.  Additionally, the hypertensive  
response to SE may also contribute to cardiac stunning due to increased 
afterload (Kloner and Jennings 2001).  Together these studies suggest a 
mechanism by which SE produces neurogenically mediated cardiac stunning 
through intense activation of the SymNS and increased plasma 
catecholamine levels (Legriel, et al. 2008, Rona 1985, Simon, et al. 1984, 
Walton 1993, Wittstein, et al. 2005).  It has been demonstrated in animals 
that Li-pilocarpine induced SE produces a chronotropic and inotropic 
response associated with cardiac injury (Bealer, et al. 2010, Metcalf, et al. 
2009a); however, it was unknown if SE-induced a contractile dysfunction that 





a recoverable contractile dysfunction similar to stunning in humans, 
demonstrated by decreased LV chamber volume, diminished lusitorpy, and 
increased ventricular wall thickness without gross cardiac damage—which 
returned to Cont values by 10 days.  
Abnormalities of ventricular function can be separated into problems 
of ventricular filling (diastole) and ventricular empting (systole). Systolic 
ventricular dysfunction, as is precipitated by heart failure, refers to the loss 
of cardiac inotropy that results in a diminished stroke volume, a 
compensatory rise in end-diastolic pressure, and increased LV end-diastolic 
volume due to ventricular hypertrophy, dilation. Consequently, in heart 
failure, ejection fraction can become decreased as stroke volume decreases 
and end-diastolic volume increases. However, even in the presence of normal 
systolic ventricular performance (i.e., normal ejection fraction), abnormalities 
of diastolic ventricular filling can occur because of low ventricular 
compliance, thereby reducing stroke volume.  Diastolic dysfunction in the 
setting of normal systolic function may be due to obstruction of left 
ventricular filling, impaired left ventricular distensibility, or active 
relaxation (Zile, et al. 2004). This results in appreciable reduction in both 
stroke volume and end-diastolic volume such that ejection fraction does not 
change. The present experiments demonstrate a reduction in both stroke 
volume and end-diastolic volume, which produced a slight increase in ejection 





dysfunction. It has been suggested that the mechanism of abnormal 
ventricular relaxation is due to impaired excitation-contraction coupling and 
Ca2+ regulation (see Chapter 1).  
Chronic effects and mechanisms of recovery following myocardial 
stunning are unclear.  Previous research has shown that, in animals, SE 
produces chronic alterations including LV ion channel remodeling (Bealer, et 
al. 2010), increased SymNS tone (Metcalf, et al. 2009b), arrhythmogenic 
changes to ECG and increased susceptibility to arrhythmias (Metcalf, et al. 
2009a) within 10 days. Experiments presented here demonstrate a cardiac 
dysfunction that recovers within 10 days, despite an elevated resting HR in 
anesthetized animals that have undergone SE.  We proposed that cardiac 
injury produced by SE may act as a substrate for adaptive compensatory 
cardiac remodeling to occur.  Thus, increased HR is likely due to altered ANS 
balance in response to CNS damage and is a potential compensatory 
mechanism to diminished cardiac efficiency.  Indeed it remains unknown, but 
is likely that cardiac recovery depends on adaptive compensatory cardiac 
remodeling within 10 days following SE cessation. Consequently, these 
cardiac alterations may increase risk factors that predispose patients to 
sudden cardiac death beyond the stunning period. 
In contrast to the transient LV dysfunction which appears to recover 
within 10 days following SE, cerebral edema persists and even worsens by 45 





cardiac pathology are not clear.  However, it has been shown that SE does 
produce chronic alterations in SymNS balance in the weeks following SE 
(Metcalf, et al. 2009b). Additionally, seizures, edema, or damage that affects 
areas in the central autonomic network may alter autonomic afferents or 
modify autonomic expression (Devinsky 2004). More specifically, these 
autonomic networks encompass cortical limbic areas, including the amygdala 
and insular cortex, which directly connects with subcortical regions of the 
central autonomic network, including the hypothalamus, the pons, solitary 
tract nucleus, and ventrolateral medulla (Devinsky 2004, Kanter, et al. 1991, 
Kanter, et al. 1996).  The T2-weighted images presented in Fig. 4.2 
demonstrate pervasive edema through the limbic and cortical systems. Since 
these brain regions are critical in regulating SymNS activity, excitatory 
stimulation, damage or alteration to these brain areas could result in altered 
SymNS tone and increased susceptibility to sudden cardiac death. 
Isoflurane is known to increase heart rate and decrease respiration 
rate in a dose-dependent manner and greatly depends upon body 
temperature and oxygen saturation (Pacher, et al. 2008).  The reason for the 
increased dose of isoflurane necessary to reach the same plane of  anesthesia 
following SE is not clear; however, it is likely that central nervous system 
damage or increased SymNS tone could alter the pharmacodynamics and 
pharmacokinetics of isoflurane.  Alternatively, increased HR also may be a 





SE—further investigation is needed  to clarify differential affects of 
anesthesia following SE. 
Animals that underwent Li-pilocarpine -SE can develop spontaneous 
seizures in the months following recovery.  Although these animals were not 
video monitored, no observable motor seizures were noted from the time of 
SE termination with VPA through 45 days.   
Following an episode of SE patients are at an increased risk for 
mortality by an unknown mechanism.  Cardiac stunning has been reported in 
patients following prolonged seizure activity, which increases mortality risk.  
The present experiments demonstrate that SE can produce a reversible 
contractile dysfunction in rodents similar to cardiac stunning humans. 
Further, these data demonstrate that cardiac dysfunction resulting from SE 
can recover independently of brain damage.  However, cerebral edema may 
contribute to alterations in sympathovagal balance.  Together these results 
suggest prolonged seizures cause neurogenically mediated cardiac stunning, 
which increase mortality risk. Cardiac stunning is a potentially preventable 
and treatable disorder that warrants cardiac monitoring of all patients 
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EX VIVO MEASUREMENTS OF CALCIUM TRANSIENTS  
 





  Intracellular calcium (Ca2+) concentration in myocytes is one of the 
most important factors contributing to increased myocardial contraction and 
relaxation.  It has been proposed that cardiac stunning alters excitation-
contraction band coupling and represents a favorable substrate for triggered 
arrhythmias due to enhanced susceptibility to Ca2+  overload  (Gao, et al. 
1995) and Ca2+ myofilament proteolysis (Gao, et al. 1997). Previously (see 
Chapter 4) MRI scans demonstrated a reversible cardiac dysfunction, similar 
to stunning, characterized by incomplete relaxation of the left ventricle 
following status epilepticus (SE).  The mechanism that impairs myocardial 
relaxation is believed to involve alterations in Ca2+ handling (Apstein and 
Lorell 1988).  Thus, we propose that status epilepticus alters cardiac function 
through changes in Ca2+ regulation and sensitivity to cardiac troponin.  To 





were preformed to measure the time constant of cytosolic Ca2+ decline (tau) 







 Retired breeder Hartley Guinea pigs were obtained from a commercial 
supplier (Charles River, Wilmington, MA). Animals were individually housed 
with ad libitum access to food and water and maintained at 22oC on a 12 hr: 
12 hr, light: dark schedule. All experimental procedures were approved by 




SE was induced using lithium-pilocarpine, using previously described 
methods (Uva, et al. 2008). Briefly, an injection of lithium (127 mM/kg ip, 
Sigma) was given 18-24 hrs prior to pretreatment with methylscopalamine (1 
mg/kg ip, 30 min, Sigma) and administration of pilocarpine (100 mg/kg ip, 
Sigma). Control animals were administered saline vehicle in place of 
pilocarpine. The modified Racine Scale was used to evaluate seizure activity 
(Racine 1972). Approximately 30 min following pilocarpine treatment stage 4-
5 seizures were observed. After 90 min of SE, seizure activity was terminated 





Guinea Pig Langendorff Heart Preparation 
Guinea pig ventricles were perfused as Langendorff preparations 
which is described elsewhere (Poelzing and Veeraraghavan 2007, Radwanski, 
et al. 2010). Briefly, guinea pigs (0.8-1.0 kg) were anesthetized with sodium 
pentobarbital (30 mg/kg ip). Next, their hearts were rapidly excised, the atria 
removed and perfused as Langendorff preparations (perfusion pressure 55 
mmHg) with oxygenated (100% O2) Tyrode solution at 36.5°C of the following 
composition (in mM): CaCl2 2, NaCl 140, KCl 4.5, dextrose 10, MgCl2 1, and 




  A calcium mapping system, developed by the Poelzing laboratory at 
the University of Utah, was used in these experiments as previously 
described (Radwanski, et al. 2010). Briefly, cardiomyocyte Ca2+ handling 
dynamics were quantified by optical mapping of intracellular Ca2+ with the 
calcium indicator Indo-1-AM. Intracellular Ca2+ was measured using dual 
wavelength collection. Excitation light obtained from a 1000-W mercury arc 
lamp was filtered at 350 ± 10 nm and directed through a flexible liquid light 
guide to the preparation. Fluorescent light from the preparation was collected 
by a 150 mm achromatic lens (BK7/Flint, Ealing, Rocklin, CA) incident on a 
515 DCXR dichroic mirror set at a 45 angle to the recording surface. 





mirror onto a 445-nm dichroic long-pass mirror which was positioned 
between the lenses of the tandem lens assembly at a 45° angle. All 
wavelengths above 445 nm were transmitted to one CCD and wavelengths 
below 445 nm to another CCD camera. For ratiometric optical mapping as 
described previously (Laurita, et al. 2003), transmitted and reflected 
fluorescent light was limited to 485 ± 10 nm and 405 ± 10 nm, respectively, by 
using optical interference filters. The ratiometric calcium transients 
(arbitrary units (AU)) were calculated as follows (Katra, et al. 2004): [Ca2+]i = 
(CaF405-BF405)/(CaF485-BF485), where CaF405 and CaF480 were the signal 
intensities during Indo-1 perfusion in the 405 nm and 480 nm filtered 
signals. BF405 and BF485 were the signal intensities from the 405 and 480 nm 
filtered signals in the absence of Indo-1. This ratio has been previously used 
to demonstrate differences in diastolic Ca2+ concentration and Ca2+ transient 




 Motion was further reduced by perfusion with 1.5 mM 2,3-butanedione 
monoxime (BDM). Hearts were stimulated with a unipolar silver wire placed 
on the anterior epicardial surface close to the equatorial plane of the ventricle 
being mapped at 1.5 times the stimulation threshold with a basic cycle length 
(BCL) of 200ms.  To quantify the rate of intracellular Ca2+  recovery to 





decline phase) was measured as the time constant () of a single exponential 
fit as previously described (Bers and Berlin 1995, Clark, et al. 1996, Katra, et 




Procedures for rapid pacing induced arrhythmias are described in 
detail elsewhere (Radwanski, et al. 2010). Briefly, a 20-beat drive train 
stimulus (S1; at BCL of 400 ms) was delivered to the anterior epicardial 
surface of the right ventricular base. Using the same drive train a second 
premature stimulus (S2) was delivered to the epicardial left ventricular apex. 
To reach refractoriness or induce arrhythmias, the S1-S2 interval was 
sequentially shortened by 10 ms. Susceptibility to rapid pacing–induced 
arrhythmias was determined using the shortest cycle length for S1-S2 
interval that maintained 1:1 capture. A premature ventricular complex (PVC) 
was defined as any nonrecurring QRS complex that occurred with in <1.5 SD 
of the intrinsic cycle length (Radwanski, et al. 2010).Ventricular tachycardia 






Pacing -induced Arrhythmias 
 Following 90 min of pilocarpine induced SE, three of four animals had 





induced.  Twenty-four hours following SE, one of three animals had VT 
induced with two animals losing 1:1 capture before arrhythmias could be 
induced.  These results suggest that increased susceptibility to arrhythmias 
acutely following 90 min of SE, but not at 24 hrs when compared to Cont.  
 
 
Ex Vivo Calcium Transients 
Fig. 5.1 shows rate of Ca2+ transient, tau, at BCL 200 ms measured in 
Cont (n=4), 90 min following SE (n=3), and 24 hrs following SE (n=3).  These 
data show no significant difference in the Ca2+ transients following SE at 





 These studies demonstrate that at either 0 hrs or 24 hrs following 90 
min of SE, Ca2+ transients were not altered in the Langendorff isolated heart 
preparation.  These results suggest that the mechanism of arrhythmias may 
not be mediated by Ca2+ dysregulation intrinsic to the heart.  Further, since 
these hearts are denervated from autonomic influence, these results suggest 
that following prolonged seizure activity an intact autonomic nervous system 
is necessary to constitute cardiac dysfunction and manifest both acute and 
chronic adaptations. 
 Previously it has been reported in patients and animal models that SE 





















Figure 5.1.  Panel A shows Ex Vivo Ca2+ transients at 0 hrs (n=3) and 24 hrs 
(n=3) following SE and in cont (n=3) guinea pigs. Panel B shows tau, a 
measurement of Ca2+ decay, at a basic cycle length (BCL) of 200 ms. No 
significant difference in Ca2+ transients was observed in any SE animal when 







Kreisman, et al. 1993, Legriel, et al. 2008, Manno, et al. 2005, Painter, et al. 
1993, Sakuragi, et al. 2007, Young, et al. 1985), similar to cardiac stunning 
(Pomblum, et al. 2010), which is characterized by a myofilament loss of 
cardiac troponin, increased sympathetic tone, altered cardiac hemodynamic, 
prolonged QT interval, and increased susceptibility to arrhythmias (Bealer, 
et al. 2010, Metcalf, et al. 2009a, Stollberger and Finsterer 2004). While all 
these changes are known cardiac risk factors that increase mortality, the 
mechanism(s) of cardiac stunning and increased susceptibility to arrhythmias 
following SE remains unknown. 
 One potential mechanism that may produce both stunning and 
arrhythmias following prolonged seizure activity is intense sympathetic 
activation and catecholamine mediated tachycardic ischemia. The major 
mechanism of intracellular diastolic Ca2+ regulation is discussed in detail in 
Chapter 1. Generally, prolonged tachycardia can induce intracellular 
diastolic Ca2+ overload that damages and impairs myofilament function 
(Carroll, et al. 1983). As a result, cardiac electrophysiology is altered 
producing a contractile dysfunction that increases arrhythmogenic activity 
(Anderson 2003, Bernstein, et al. 2000, Devinsky 2004, Freeman 2006, 
Lathers and Schraeder 1987, Metcalf, et al. 2009b, Nei, et al. 2000, Opherk, 
et al. 2002, Ryvlin, et al. 2006, Teplitz, et al. 2005). Consequently, 





activation may result in diastolic dysfunction, such as cardiac stunning (Gao, 
et al. 1995, Przyklenk, et al. 1987). 
A major hallmark of a diastolic dysfunction induced by ischemic injury 
is impaired myocardial relaxation (Gilbert and Glantz 1989, Lorell 1991). 
Various studies have shown that there is a relationship between the time 
constant of left ventricular pressure decline, a measure of impaired 
relaxation, and tau, the time constant of cytosolic Ca2+ decline (Applegate, et 
al. 1987, Serizawa, et al. 1987, Serizawa, et al. 1981). Thus, the mechanisms 
that produce impaired myocardial relaxation following ischemic injury are 
believed to involve abnormalities of Ca2+ handling. As discussed in previous 
Chapters, both MRI scans and cardiac output measurements in rats following 
SE demonstrate impaired myocardial relaxation following seizure cessation; 
however, results of these experiment demonstrate that Tau is not altered in 
the isolated guinea pig heart and suggest Ca2+ dysregulation, due to altered 
cytosolic reuptake, does not mediate cardiac diastolic dysfunction following 
SE.  This would indicate that diastolic dysfunction is not intrinsic to the 
heart and may depend on external factors such as autonomic tone, circulating 
catecholamines, afferent information to higher cardiac brain centers, 
endocrine effects, and hemodynamic factors.  
Several limitations of these experiments should be considered in the 
interpretation of these data and when considering potential mechanisms of 





transients may be too small to be detected by this method; even subtle 
changes in Ca2+ regulation could potentially increase susceptibility to 
arrhythmias and alter cardiac function. Second, the perfusion time during 
the Langendorff preparation may act to rescue cardiac myocytes from 
tachycardic ischemia by removing sympathetic influence and adrenoceptor 
mediated regulation. Third, cardiac arrhythmias produced by atrial 
fibrillation or damage to pace maker cells may be prevented by removal of the 
atria as part of the Langedorff preparation. SE-induced changes in 
automaticity are unknown.  Fourth, a longer period of recovery following SE 
may be necessary to manifest adaptive cardiac remodeling.  Remodeling of 
potassium channels LV myocytes has been shown to occur within 10 ten days 
of SE (Bealer, et al. 2010); however, changes in ion channel expression before 
this time point are unknown. 
Results of these experiments suggest that Ca2+ transients, under the 
conditions studied and given the four caveats listed above, are not major 
contributors to diastolic dysfunction in the isolated guinea pig heart following 
an episode of SE.  However, results of these studies may be inconclusive due 
to the absence of SymNS influence and a lack of sensitivity likely necessary 
to detect a more subtle effect. Moreover, these results are in contradiction 
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During the 30-day period following status epilepticus (SE), patients are 
at an increased risk for mortality. Previously, it has been demonstrated that 
SE produces a sudden and prolonged activation of the sympathetic nervous 
system (Benowitz, et al. 1986) and hypersecretion of catecholamines that act 
to overstimulate β-adrenergic receptors on cardiac muscle (Walton 1993).  
Using these prior observations, we proposed that cardiac 
overstimulation produces tachycardic ischemia reperfusion and contractile 
dysfunction following SE termination—which are well established risk 
factors for sudden cardiac death. Further, we proposed that a sympathetic 
blockade would prevent SE-induced cardiac myofilament damage, thereby 
reducing mortality risk.   
To test these hypotheses, several different animal models of SE were 
used, with and without administration of a β-1 receptor antagonist, to 
evaluate cardiac hemodynamic parameters, left ventricular function, cardiac 





induced susceptibility to arrhythmias at various time points following seizure 
cessation.  
Chapter 2 of this dissertation investigated the effect of intense 
activation of the SymNS on BP, HR,  cardiac damage, alterations in cardiac 
electrical activity, susceptibility to arrhythmias and potential cardiac 
protection with a β-1 receptor antagonist using a rat model of pilocarpine 
induced SE.  Results from these studies demonstrated that SE produced 
hypertension, tachycardia, cardiac damage, and increased susceptibility to 
arrhythmias.  Further, these results also demonstrated that cardiac therapy 
during prolonged seizure activity with a β-1 adrenergic antagonist 
significantly prevented sympathetically mediated tachycardia, cardiac 
damage, arrhythmogenic electrical alterations, and reduced susceptibility to 
arrhythmias for 10-12 days following SE termination. However, 
administration of a β -1 receptor antagonist did not prevent hypertension 
during SE.  These findings demonstrated that cardiac effect of SE are 
potentially preventable with appropriate cardiac therapy and thereby reduce 
SE related mortality.  
Although a loss of cTnI was demonstrated to occur during SE, which 
indicates impaired excitation-contraction machinery and suggests impaired 
inotropy, it does not completely explain cardiac stunning following seizure 
cessation.  Several studies have shown that stunned myocardium responds 





1995), indicating contractile reserves remains and suggest that cardiac 
troponins may not be damaged sufficiently to independently limit inotropy. It 
is not yet clear what else may contribute to cardiac stunning such as, 
damaged or inactivated membrane bound receptors like β-1 adrenergic 
receptor, ion channels,  ryanodine receptors, or phospholamban.  
Alternatively, remodeling of SymNS innervations may also reflect changes in 
inotropy and lusitropy.  In any case, the unique contributions to cardiac 
stunning by different myocyte components remain to be investigated.  
 Chapter 3 of this dissertation further investigated potential effects of β 
-1 receptor overstimulation during SE and effects of adrenergic antagonism 
in a rat model of unilaterally stimulated SSLSE. More specifically, we 
investigated the proposal that SE results in diminished cardiac function 
through a neurogenic mechanism, such as cardiac stunning, in which 
increased sympathetic tone and high levels of plasma catecholamines induce 
cardiac overstimulation and produce cardiac dysfunction.  Results of these 
studies demonstrate diminished cardiac ventricular function within 24 hrs, 
characterized by reduced CO, LVP dP/dt Max and Min, which is consistent 
with neurogenically mediated cardiac stunning in humans.  Further, these 
studies show that administration of the β-1 receptor antagonist during 
SSLSE prevents development of cardiac contractile dysfunctions, which occur 
within 24 hrs. Moreover, SSLSE produced a cardiac dysfunction that was 





that it is SE and not the muscarinic effects of pilocarpine that are mediating 
cardiac dysfunction.  Together these results provide a potential mechanism 
and therapeutic strategy to reduce mortality risk by prevention of adverse 
cardiac effects caused by SE.    
 In Chapter 4 MRI scans were used to evaluate LV function acutely and 
chronically following SE using a rat model of pilocarpine induced SE. Results 
from these studies demonstrate that SE induces, albeit recoverable, LV 
contractile dysfunctions similar to cardiac stunning in humans.  SE produces 
a diastolic dysfunctions characterized by decreased LV stroke volume; end-
diastolic volume; near normal ejection fraction, indicative of impaired 
lusitropy; and increased  LV wall thickness, without irreversible gross 
damage or apparent remodeling.  MRI scans of the brain, however, did 
demonstrate gross damage and edema throughout the hippocampus, cortex, 
and ventricles, which persisted for more than 45 days.  
 Results from nearly every experiment indicated a diastolic dysfunction, 
including: prolonged QT interval at 24 hrs and 2 weeks, with no appreciable 
change in QRS; pressure measurements demonstrated a reduction in LVP 
dP/dt min, indicative of reduced relaxation; MRI imaging confirmed 
decreased SV and end-diastolic volume, with near normal ejection fraction.  
The primary mechanism whereby reduced lusitropy occurs is most likely near 
the end of the cycle of excitation-contraction coupling in the myocyte. At this 





concentration of Ca2+ in the vicinity of the sacromere is rapidly reduced, 
allowing the Ca2+ to leave its binding sites on troponin-C and mediates actin 
disengagement from myosin. This step allows for rapid and complete 
relaxation of the myocyte.  If  SE induces or impairs the reduce rate of  Ca2+ 
sequestration, by oxidative damage of SERCA or activation of calpains that 
degrade TnI for example, then the rate and extent of relaxation can become 
decreased.  Ultimately, this will reduce the rate of ventricular filling 
resulting in a diastolic dysfunction. 
 In Chapter 5, we investigated Ca2+ dysregulation as potential 
mechanism that produces SE-induced cardiac dysfunction using a guinea pig 
model of pilocarpine induced SE.  Results of these studies suggest that 
altered Ca2+ transients are not a mechanism of SE-induced cardiac stunning.  
However, these results are not consistent with the in vivo data collected in 
Chapters 2, 3, and 4, which suggests a diastolic dysfunction. Further, these 
experiments have several limitations that are discussed in Chapter 5.  
Notably, isolated cardiac preparations are essentially denervated and lack 
autonomic influence and afferent feedback mechanism to higher brain 
centers that affect cardiac regulation. This is highly suggestive that an intact 
autonomic nervous system or cardiac brain centers contributes directly to 
altered cardiac function.   
 While these studies have primarily focused on cardiac effects of SE, 





contribute to cardiac risk factors associated with sudden unexplained death 
in epilepsy (SUDEP).  Seizures have been shown to exert effects on cardiac 
function (Schuele 2009) and are predominantly associated with 
tachyarrhythmias, and less frequently with bradyarrhythmias (Kerling, et al. 
2009).  Kerling, et al. demonstrated that cardiac postganglionic denervation 
occurred in patients with epilepsy and may be responsible for ictal asystole. 
These investigators conclude that altered cardiac SymNS innervations 
restrict heart rate modulation and indicate a postganglionic cardiac 
catecholamine disturbance, which increases risk of arrhythmias and SUDEP 
(Kerling, et al. 2009).  Results presented in this dissertation also 
demonstrated a cardiac dysfunction that was mediated by catecholamine 
disturbance.  Potentially, there are three mechanisms increasing cardiac 
arrhythmias and mortality risk following SE or repeated seizures: 1) a 
sufficient period of tachycardia or bradycardia to produce an ischemia 
reperfusion event similar to cardiac stunning, 2) seizure induced 
postganglionic altered cardiac autonomic innervations and 3) altered higher 
brain centers that influence and control the heart and ANS.  While this 
dissertation demonstrated SE induced cardiac stunning after 90 min of SE, 
the minimum period of  SymNS mediated cardiac effects needed to produce a 
cardiac dysfunction during SE or repeated seizures is not known and requires 
further investigation.  Additionally, histological evaluation of cardiac SymNS 





amygdala, following SE or repeated seizures has not been performed and 
would contribute further information on similarities or difference between 






Role of Hypothalamic Pituitary Adrenal Axis 
SE-induced brain damage and inflammation may affect critical areas 
in the brain associated with autonomic tone and regulation of the hormonal 
systems (Devinsky 2004, Kanter, et al. 1991, Kanter, et al. 1996).  Indeed, 
alterations to these systems may increase cardiac associated risk factors.  As 
an example, alterations in the HPA axis in depression are known to increase 
mortality (Kanner and Balabanov 2002). Additionally, it is known that 
activation of the HPA axis by stressful stimuli from a physiological or 
psychological disturbance is an essential component of the body’s homeostatic 
system (De Kloet, et al. 1998, Juruena, et al. 2004, Thomson and Craighead 
2008, Tsigos and Chrousos 2002). However, the effects of SE on the HPA axis 
are not established, despite the fact that chronic stress and brain damage 
following seizure cessation would most likely contribute. Although there are 
many potential alterations to explore such as alterations in glucocorticoid  
and mineralocorticoid receptor expression, brain derived neurotrophic factor 
expression, or SSRI treatments, in clinical research the DEX/CRH challenge 





established phenomenon in human aging and chronically stressful conditions 
(Heuser 1998). The combined DEX/CRH challenge test was designed to detect 
the inhibitory feedback system and could be used to determine the 
responsiveness of the HPA axis inhibitory feedback mechanism in rats 
following SE (Hatzinger, et al. 1996).  
 
 
Cardiac and CNS Protection 
Treatment with a β -1 receptor antagonist demonstrated a beneficial 
effect and exposes a mechanism by which SE induces cardiac deficits.  
However, potential consequences of preventing tachycardia during SE on 
CNS damage are still not clear.  Nevertheless, results of these studies 
demonstrate that cardio-protective therapy with a β -1 receptor antagonist, 
which blocks tachycardia during SE, does not increase risk of CNS neuronal 
death or damage as a result of altered or diminished perfusion pressure.  
Further study is needed to evaluate the effects of hypertension and 
tachycardia during seizure activity on CNS damage. Such studies could use 
various administrations of β-antagonists and evaluate brain damage using 
Fluoro-Jade B imaging or MRI scans (Nairismagi, et al. 2006).  Moreover, we 
used atenolol, which does not cross the blood brain barrier and therefore did 
not alter seizure severity; future studies that pursue a therapeutic strategy to 





β-antagonists that due cross the blood brain barrier as they may provide a 




Myocardial injury resulting from either ischemia or cardiomyopathy 
can cause changes in the SymNS innervations of cardiac tissue resulting in 
increased SymNS stimulation and nerve sprouting (Cao, et al. 2000b, Chen, 
et al. 2007, Igawa, et al. 2000, Li, et al. 2004). Changes in SymNS 
innervation are well established to increase the risk of ventricular 
hypertrophy, tachyarrhythmias, ventricular fibrillation, and sudden cardiac 
death (Airaksinen 1999, Anderson 2003, Cao, et al. 2000a, Cao, et al. 2000b, 
Chen, et al. 2007). However, the effects of SE on the SymNS innervations of 
the heart have not been systematically studied.  It has been proposed that 
cardiac damage in SE is similar to that observed in the context of ischemia 
reperfusion injury (Harrigan, et al. 1994); thus it is anticipated that changes 
in the SymNS innervations of the heart following SE should be comparable. 
Therefore, future studies should histologically examine the neuronal 
innervations of cardiac tissue in SE-induced rats. This can be accomplished 
by comparison of sectioned rat hearts 2 weeks after SE that are stained for 
tyrosine hydroxylase, norepinephrine transporter, and the pan neuronal 
marker protein gene product in cardiac innervations (Li, et al. 2004). SE has 





hyperactivity, in both the interictal and postictal periods. Changes in SymNS 
innervations of the heart combined with cardiac damage and remodeling may 




 Two mechanisms of catecholamine induced myocardial stunning have 
been proposed in the literature: (1) direct toxic effect on myocytes resulting in 
an excitation-contraction coupling dysfunction, indicative of a diastolic 
dysfunction; and (2) vasomotor constriction or spasm of the coronary 
microcirculation that results in a reversible ischemia/reperfusion injury (Bolli 
1990). In either case, both mechanisms may lead to intracellular Ca2+ 
overload or oxidative stress resulting in catecholamine induced injury and 
may represent a form of myocardial stunning (Bolli 1990, Gao, et al. 1995).   
The pattern and the time course of LV dysfunction in these experiments 
demonstrate the most salient features of acute catecholamine induced 
myocardial stunning, including  rapid development of profound LV diastolic 
dysfunction;  significant hemodynamic compromise;  a large discrepancy 
between the severity of LV contractile impairment and a modest rise in 
serum markers of myocardial damage (such as cTnI); complete reversal of 
myocardial dysfunction within weeks of SE cessation; and cardiac protection 
by inhibition of adrenergic activation of the heart.  These results also suggest 





provided by relieving myocardial ischemia during seizures, improving systolic 
function with inotropic agents postseizure, or  decreasing cardiac distention 
(Little and Applegate 1993).  
  The importance of using several animal models to study SE related 
mortality in this dissertation allowed for insights into a variety of 
mechanisms that contribute to increased mortality risk and to the initiation 
of sudden death.  In this dissertations two models were used, Li-pilocarpine 
and SSLSE.  While both models similar produced SE, the SSLSE model 
allowed for investigation of seizure induced cardiac effects without the 
muscarinic effect of pilocarpine.  Regardless of the model used, similar 
cardiac dysfunctions were evident in both and were demonstrated by cardiac 
electrophysiology, direct LV pressure measurements and noninvasive MRI 
techniques.  Together these consistent results strongly suggest that the 
cardiac effect produced by SE are model independent and are a direct result 
of seizure activity.  
 Overall, we conclude that SE produces sympathetically mediated 
cardiac dysfunction that mimics cardiac stunning in humans, which increases 
mortality and morbidity. Further, this cardiac dysfunction and the associate 
mortality risk can be reduced by pharmacotherapy during SE with a β-
receptor antagonist. Moreover, results presented in this dissertation provide 
a major mechanism by which prolonged seizures and subsequent sympathetic 





cardiac stunning is a potentially preventable and treatable disorder that 
warrants cardiac monitoring of all patients following severe and prolonged 
seizure activity. Future studies should further investigate potential 
mechanisms and treatment strategies to reduce mortality and morbidity in 
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